Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:sirolimus
go back to main search page
Accession:CHEBI:9168 term browser browse the term
Definition:A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.
Synonyms:exact_synonym: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
 related_synonym: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone;   Antibiotic AY 22989;   Formula=C51H79NO13;   InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1;   InChIKey=QFJCIRLUMZQUOT-HPLJOQBZSA-N;   Rapamune;   SMILES=[H][C@]1(CC[C@@H](O)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC;   rapamycin;   sirolimusum
 alt_id: CHEBI:45276;   CHEBI:67812
 xref: CAS:53123-88-9;   DrugBank:DB00877;   Drug_Central:2446;   HMDB:HMDB0015015;   KEGG:C07909;   KEGG:D00753;   KNApSAcK:C00018055;   LIPID_MAPS_instance:LMPK06000003
 xref_mesh: MESH:D020123
 xref: PDBeChem:RAP;   PMID:19587680;   PMID:22960739;   PMID:22981852;   PMID:22984623;   PMID:24341993;   PMID:24409289;   Reaxys:5848501;   Wikipedia:Rapamycin


show annotations for term's descendants           Sort by:
sirolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin increases expression ISO Sirolimus results in increased expression of A2M mRNA CTD PMID:21865292 NCBI chr 6:121,612,920...121,656,197
Ensembl chr 6:121,612,335...121,656,186 		JBrowse link
G Abca1 ATP-binding cassette, sub-family A member 1 multiple interactions
increases expression		 ISO [Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Sirolimus results in increased expression of ABCA1 mRNA		 CTD PMID:17016853 PMID:21865292 NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895 		JBrowse link
G Abcb1a ATP-binding cassette, sub-family B member 1A affects metabolic processing
affects transport		 ISO ABCB1 protein affects the metabolism of Sirolimus
ABCB1 protein affects the transport of Sirolimus		 CTD PMID:15707415 PMID:15760093 PMID:15964407 NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575 		JBrowse link
G Abcc2 ATP-binding cassette, sub-family member 2 decreases expression ISO Sirolimus results in decreased expression of ABCC2 mRNA CTD PMID:11589784 NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179 		JBrowse link
G Abcc8 ATP-binding cassette, sub-family C member 8 decreases expression ISO Sirolimus results in decreased expression of ABCC8 mRNA CTD PMID:21865292 NCBI chr 7:45,753,952...45,829,441
Ensembl chr 7:45,753,947...45,829,457 		JBrowse link
G Abcd3 ATP-binding cassette, sub-family D member 3 decreases expression ISO Sirolimus results in decreased expression of ABCD3 protein CTD PMID:36214828 NCBI chr 3:121,552,553...121,609,851
Ensembl chr 3:121,552,423...121,608,951 		JBrowse link
G Abtb3 ankyrin repeat and BTB domain containing 3 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of ABTB3 mRNA] CTD PMID:21245298 NCBI chr10:85,220,835...85,496,156
Ensembl chr10:85,222,678...85,496,156 		JBrowse link
G Acadl acyl-Coenzyme A dehydrogenase, long-chain multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]] CTD PMID:25045214 NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436 		JBrowse link
G Acadm acyl-Coenzyme A dehydrogenase, medium chain multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]] CTD PMID:25045214 NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269 		JBrowse link
G Ace2 angiotensin converting enzyme 2 decreases expression ISO Sirolimus results in decreased expression of ACE2 mRNA CTD PMID:21865292 NCBI chr  X:162,922,338...162,971,414
Ensembl chr  X:162,922,328...162,971,416 		JBrowse link
G Acer2 alkaline ceramidase 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] CTD PMID:21245298 NCBI chr 4:86,792,585...86,853,059
Ensembl chr 4:86,792,633...86,853,059 		JBrowse link
G Acta2 actin alpha 2, smooth muscle, aorta multiple interactions ISO
EXP		 [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]		 CTD PMID:17908691 PMID:35405287 NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990 		JBrowse link
G Actb actin, beta increases expression
multiple interactions		 EXP Sirolimus results in increased expression of ACTB mRNA
[Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA		 CTD PMID:7503980 NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509 		JBrowse link
G Agt angiotensinogen multiple interactions ISO Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium] CTD PMID:21613610 NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445 		JBrowse link
G Aifm1 apoptosis-inducing factor, mitochondrion-associated 1 decreases expression
multiple interactions		 ISO Sirolimus results in decreased expression of AIFM1 protein
[7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein]		 CTD PMID:15767555 PMID:16497721 NCBI chr  X:47,563,821...47,602,440
Ensembl chr  X:47,563,821...47,602,440 		JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions
decreases phosphorylation
affects phosphorylation
increases phosphorylation		 ISO
EXP		 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased phosphorylation of AKT1 protein; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]
[Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Resveratrol results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]
Sirolimus results in decreased phosphorylation of AKT1 protein
Sirolimus affects the phosphorylation of AKT1 protein
[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein; Sirolimus results in increased phosphorylation of AKT1 protein
resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]		 CTD PMID:15806154 PMID:18495876 PMID:18622747 PMID:19176369 PMID:21092744 More... NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318 		JBrowse link
G Akt1s1 AKT1 substrate 1 multiple interactions EXP
ISO		 [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of AKT1S1 protein; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of AKT1S1 protein		 CTD PMID:24304514 NCBI chr 7:44,498,648...44,504,845
Ensembl chr 7:44,498,415...44,504,845 		JBrowse link
G Akt2 thymoma viral proto-oncogene 2 multiple interactions ISO [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein; Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein CTD PMID:17908691 NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251 		JBrowse link
G Alpl alkaline phosphatase, liver/bone/kidney multiple interactions EXP Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]] CTD PMID:33450223 NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695 		JBrowse link
G Angptl6 angiopoietin-like 6 increases expression ISO Sirolimus results in increased expression of ANGPTL6 mRNA CTD PMID:21865292 NCBI chr 9:20,785,104...20,791,116
Ensembl chr 9:20,785,104...20,791,023 		JBrowse link
G Aopep aminopeptidase O multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA] CTD PMID:21245298 NCBI chr13:63,112,707...63,473,910
Ensembl chr13:63,112,707...63,473,910 		JBrowse link
G Apod apolipoprotein D affects localization ISO Sirolimus affects the localization of APOD protein CTD PMID:28182653 NCBI chr16:31,115,010...31,133,626
Ensembl chr16:31,115,010...31,133,626 		JBrowse link
G App amyloid beta precursor protein decreases expression
increases expression		 ISO
EXP		 Sirolimus results in decreased expression of APP protein modified form
Sirolimus results in increased expression of APP protein modified form		 CTD PMID:20542014 NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654 		JBrowse link
G Aqp2 aquaporin 2 multiple interactions
decreases expression		 ISO rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of AQP2 protein] CTD PMID:19656910 NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428 		JBrowse link
G Ar androgen receptor multiple interactions
increases activity
increases expression		 ISO [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus affects the reaction [Testosterone results in increased expression of AR protein]; Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein]
Sirolimus results in increased expression of AR protein		 CTD PMID:18776922 PMID:21036700 NCBI chr  X:97,192,363...97,366,824
Ensembl chr  X:97,192,375...97,366,821 		JBrowse link
G Asns asparagine synthetase multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA] CTD PMID:11355896 NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254 		JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of ATF3 mRNA CTD PMID:25307878 NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein]		 CTD PMID:24057571 PMID:29870746 NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO [Sirolimus co-treated with hydroquinone] results in decreased expression of ATF6 protein CTD PMID:37148176 NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340 		JBrowse link
G Atg4a autophagy related 4A, cysteine peptidase increases expression EXP Sirolimus results in increased expression of ATG4A mRNA CTD PMID:21681844 NCBI chr  X:139,854,594...139,947,190
Ensembl chr  X:139,857,656...139,947,266 		JBrowse link
G Atg4b autophagy related 4B, cysteine peptidase increases expression
multiple interactions		 EXP
ISO		 Sirolimus results in increased expression of ATG4B mRNA
Sirolimus inhibits the reaction [ATG4B protein results in increased expression of HK2 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of SLC2A1 protein]		 CTD PMID:21681844 PMID:36336208 NCBI chr 1:93,682,627...93,717,328
Ensembl chr 1:93,679,222...93,718,332 		JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression		 ISO
EXP		 [Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [Particulate Matter results in increased expression of ATG5 protein]]
[Sirolimus co-treated with cadmium acetate] results in increased expression of ATG5 mRNA; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]
Sirolimus results in increased expression of ATG5 mRNA; Sirolimus results in increased expression of ATG5 protein		 CTD PMID:19682553 PMID:29128638 PMID:29505745 PMID:29781141 PMID:29870746 More... NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287 		JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA CTD PMID:31676321 NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575 		JBrowse link
G Aurkb aurora kinase B multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA CTD PMID:19016759 NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA] CTD PMID:11355896 NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267 		JBrowse link
G Bax BCL2-associated X protein affects localization
multiple interactions
increases expression		 ISO
EXP		 Sirolimus affects the localization of BAX protein
[Curcumin co-treated with Sirolimus] results in increased expression of BAX; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BAX protein]; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BAX protein]; Sirolimus promotes the reaction [hydroquinone results in increased expression of BAX protein]
Sirolimus results in increased expression of BAX protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [sophoricoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein]
Sirolimus results in increased expression of BAX mRNA; Sirolimus results in increased expression of BAX protein		 CTD PMID:11602639 PMID:15782132 PMID:19373661 PMID:19922502 PMID:29054700 More... NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322 		JBrowse link
G Bbc3 BCL2 binding component 3 multiple interactions ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] CTD PMID:19560264 PMID:20686837 NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130 		JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions
decreases expression
affects expression		 ISO
EXP		 [Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BCL2 protein]; Sirolimus inhibits the reaction [Colistin results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; Sirolimus promotes the reaction [Artesunate results in decreased expression of BCL2 protein]; Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein]
Sirolimus results in decreased expression of BCL2 mRNA; Sirolimus results in decreased expression of BCL2 protein
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sirolimus inhibits the reaction [sophoricoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]
Sirolimus affects the expression of BCL2 protein		 CTD PMID:11355896 PMID:15571967 PMID:18640276 PMID:19373661 PMID:19764996 More... NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004 		JBrowse link
G Bcl2a1a B cell leukemia/lymphoma 2 related protein A1a multiple interactions EXP [Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA CTD PMID:11355896 NCBI chr 9:88,838,973...88,844,469
Ensembl chr 9:88,838,953...88,844,472 		JBrowse link
G Bcl2l1 BCL2-like 1 multiple interactions
decreases expression
increases expression		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein; Sirolimus inhibits the reaction [Colistin results in decreased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein]
Sirolimus results in decreased expression of BCL2L1 protein
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]
Sirolimus results in decreased expression of BCL2L1 mRNA; Sirolimus results in decreased expression of BCL2L1 protein
Sirolimus results in increased expression of BCL2L1 mRNA; Sirolimus results in increased expression of BCL2L1 protein		 CTD PMID:11355896 PMID:15767555 PMID:15782132 PMID:18097008 PMID:18789402 More... NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648 		JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
decreases expression		 ISO
EXP		 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA]
Sirolimus results in increased expression of BCL2L11 protein
Sirolimus results in decreased expression of BCL2L11 protein		 CTD PMID:18097008 PMID:21092744 PMID:29054700 NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467 		JBrowse link
G Bdnf brain derived neurotrophic factor multiple interactions EXP Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein]; Sirolimus inhibits the reaction [Creatine results in increased expression of BDNF protein]; Sirolimus inhibits the reaction [Ketamine results in increased expression of BDNF protein] CTD PMID:17209049 PMID:33022268 NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352 		JBrowse link
G Becn1 beclin 1, autophagy related multiple interactions
increases expression		 ISO
EXP		 [Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein]
Sirolimus results in increased expression of BECN1 protein
Sirolimus results in increased expression of BECN1 mRNA; Sirolimus results in increased expression of BECN1 protein
[Sirolimus co-treated with cadmium acetate] results in increased expression of BECN1 mRNA; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [T-2 Toxin results in increased expression of BECN1 mRNA]
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [phenanthrene results in decreased expression of BECN1 mRNA]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus promotes the reaction [Trichloroethylene results in increased expression of BECN1 protein]		 CTD PMID:20358864 PMID:21410490 PMID:26648565 PMID:26825372 PMID:27107786 More... NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112 		JBrowse link
G Bglap bone gamma carboxyglutamate protein multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]
Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]]		 CTD PMID:23111315 PMID:33450223 NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
decreases expression
increases expression		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein
Sirolimus results in decreased expression of BID protein
Sirolimus results in increased expression of BID mRNA; Sirolimus results in increased expression of BID protein		 CTD PMID:15767555 PMID:18097008 PMID:19922502 NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions
affects localization
increases expression		 ISO Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein]
Sirolimus affects the localization of BIRC2 protein
Sirolimus results in increased expression of BIRC2 protein		 CTD PMID:15571967 PMID:21357504 NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression		 ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA; Sirolimus inhibits the reaction [N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide results in increased expression of and affects the localization of BIRC5 protein]; Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein]
Sirolimus results in decreased expression of BIRC5 protein		 CTD PMID:19016759 PMID:19931998 PMID:21601561 PMID:24444656 NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569 		JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions ISO Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] CTD PMID:23111315 NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805 		JBrowse link
G Bnip3 BCL2/adenovirus E1B interacting protein 3 multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA] CTD PMID:11355896 NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248 		JBrowse link
G Btc betacellulin, epidermal growth factor family member multiple interactions ISO Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein] CTD PMID:19105244 NCBI chr 5:91,505,120...91,550,853
Ensembl chr 5:91,505,120...91,550,853 		JBrowse link
G Btk Bruton agammaglobulinemia tyrosine kinase multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA] CTD PMID:11355896 NCBI chr  X:133,443,083...133,484,366
Ensembl chr  X:133,443,085...133,484,319 		JBrowse link
G Bub1 BUB1, mitotic checkpoint serine/threonine kinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA CTD PMID:19016759 NCBI chr 2:127,642,117...127,673,790
Ensembl chr 2:127,643,036...127,673,785 		JBrowse link
G Bub1b BUB1B, mitotic checkpoint serine/threonine kinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA CTD PMID:19016759 NCBI chr 2:118,428,684...118,472,073
Ensembl chr 2:118,428,692...118,472,072 		JBrowse link
G C1qa complement component 1, q subcomponent, alpha polypeptide decreases expression ISO Sirolimus results in decreased expression of C1QA mRNA CTD PMID:21865292 NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114 		JBrowse link
G C1qc complement component 1, q subcomponent, C chain decreases expression ISO Sirolimus results in decreased expression of C1QC mRNA CTD PMID:21865292 NCBI chr 4:136,617,115...136,620,225
Ensembl chr 4:136,617,115...136,620,376 		JBrowse link
G C3 complement component 3 decreases expression ISO Sirolimus results in decreased expression of C3 mRNA CTD PMID:21865292 NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136 		JBrowse link
G Cald1 caldesmon 1 multiple interactions
increases expression		 ISO [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein
Sirolimus results in increased expression of CALD1 protein		 CTD PMID:17908691 NCBI chr 6:34,575,433...34,752,404
Ensembl chr 6:34,575,435...34,752,408 		JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] CTD PMID:21933187 NCBI chr18:61,058,704...61,121,224
Ensembl chr18:61,058,690...61,121,224 		JBrowse link
G Capn1 calpain 1 decreases activity ISO Sirolimus results in decreased activity of CAPN1 protein CTD PMID:21357504 NCBI chr19:6,038,573...6,065,855
Ensembl chr19:6,038,573...6,065,927 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of CASP1 protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of CASP1 mRNA]		 CTD PMID:30205151 PMID:31586597 PMID:35405287 PMID:36849104 NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290 		JBrowse link
G Casp12 caspase 12 decreases cleavage
multiple interactions		 EXP
ISO		 Sirolimus results in decreased cleavage of CASP12 protein
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of CASP12 protein]		 CTD PMID:20511674 PMID:29870746 NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032 		JBrowse link
G Casp2 caspase 2 multiple interactions ISO [Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] CTD PMID:15767555 NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases cleavage
increases expression
decreases activity		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Colistin results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA]
Sirolimus results in increased activity of CASP3 protein
Sirolimus results in increased cleavage of CASP3 protein
Sirolimus results in decreased activity of CASP3 protein
Sirolimus results in increased expression of CASP3 mRNA; Sirolimus results in increased expression of CASP3 protein
[Sirolimus co-treated with Resveratrol] results in increased cleavage of CASP3 protein; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; Sirolimus promotes the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus results in decreased cleavage of and results in decreased activity of CASP3 protein
Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [gelsenicine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cadmium results in increased cleavage of CASP3 protein]
Sirolimus results in increased expression of CASP3 protein modified form		 CTD PMID:14502240 PMID:15571967 PMID:15753396 PMID:15767555 PMID:15782132 More... NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724 		JBrowse link
G Casp7 caspase 7 multiple interactions
decreases activity		 ISO [Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein
Sirolimus results in decreased activity of CASP7 protein		 CTD PMID:15753396 PMID:19373661 PMID:20031680 NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein]
Sirolimus results in increased cleavage of CASP8 protein
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]		 CTD PMID:15767555 PMID:17121904 PMID:18058806 PMID:25307878 PMID:28342888 NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662 		JBrowse link
G Casp9 caspase 9 multiple interactions
decreases activity		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus inhibits the reaction [Colistin results in increased activity of CASP9 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]
Sirolimus results in decreased activity of CASP9 protein
[Swainsonine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein]
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]		 CTD PMID:15753396 PMID:15767555 PMID:16497721 PMID:17121904 PMID:18058806 More... NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287 		JBrowse link
G Cat catalase increases expression EXP Sirolimus results in increased expression of CAT protein CTD PMID:30905858 NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505 		JBrowse link
G Cav3 caveolin 3 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] CTD PMID:21245298 NCBI chr 6:112,436,466...112,449,833
Ensembl chr 6:112,436,466...112,449,833 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression ISO Sirolimus results in increased expression of CCN2 mRNA CTD PMID:21865292 NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581 		JBrowse link
G Ccna2 cyclin A2 multiple interactions
decreases expression		 ISO
EXP		 [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA
Sirolimus results in decreased expression of CCNA2; Sirolimus results in decreased expression of CCNA2 protein		 CTD PMID:7503980 PMID:8419408 PMID:19016759 PMID:19505958 NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299 		JBrowse link
G Ccnb2 cyclin B2 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA CTD PMID:19016759 NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases degradation
increases expression
decreases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1; [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of CCND1 protein; [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]
Sirolimus results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]		 CTD PMID:7532117 PMID:15753396 PMID:15767555 PMID:17121904 PMID:19105244 More... NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662 		JBrowse link
G Ccnd2 cyclin D2 multiple interactions
decreases expression		 ISO [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]
Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA]
Sirolimus results in decreased expression of CCND2 protein		 CTD PMID:15070696 PMID:15778701 PMID:17510244 NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156 		JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases stability
decreases expression		 ISO
EXP		 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]
Sirolimus results in decreased stability of CCND3 mRNA
Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]
Sirolimus results in decreased expression of CCND3 mRNA; Sirolimus results in decreased expression of CCND3 protein		 CTD PMID:10849422 PMID:12393642 PMID:15070696 PMID:15778701 PMID:15882288 NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616 		JBrowse link
G Ccne1 cyclin E1 increases expression
multiple interactions		 ISO Sirolimus results in increased expression of CCNE1 protein
Curcumin inhibits the reaction [Sirolimus results in increased expression of CCNE1 protein]		 CTD PMID:36640941 NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959 		JBrowse link
G Ccne2 cyclin E2 multiple interactions ISO [Fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] CTD PMID:19016759 PMID:27542212 NCBI chr 4:11,190,489...11,204,781
Ensembl chr 4:11,191,351...11,204,779 		JBrowse link
G Ccng2 cyclin G2 multiple interactions
increases expression		 ISO [cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]
Sirolimus results in increased expression of CCNG2 mRNA		 CTD PMID:18754885 PMID:21245298 PMID:24356939 PMID:27542212 NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090 		JBrowse link
G Ccni cyclin I multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA] CTD PMID:11355896 NCBI chr 5:93,329,796...93,354,348
Ensembl chr 5:93,329,792...93,354,354 		JBrowse link
G Cd36 CD36 molecule affects expression
multiple interactions		 ISO Sirolimus affects the expression of CD36 protein
Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA]		 CTD PMID:17016853 PMID:19640849 NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799 		JBrowse link
G Cd38 CD38 antigen multiple interactions EXP CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 PMID:24445604 NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717 		JBrowse link
G Cd68 CD68 antigen decreases expression ISO Sirolimus results in decreased expression of CD68 mRNA CTD PMID:17016853 PMID:21865292 NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979 		JBrowse link
G Cd80 CD80 antigen decreases expression EXP Sirolimus results in decreased expression of CD80 protein CTD PMID:12531798 NCBI chr16:38,277,793...38,316,682
Ensembl chr16:38,275,923...38,316,697 		JBrowse link
G Cd84 CD84 antigen increases expression ISO Sirolimus results in increased expression of CD84 mRNA CTD PMID:24356939 NCBI chr 1:171,667,261...171,718,288
Ensembl chr 1:171,667,265...171,718,285 		JBrowse link
G Cd86 CD86 antigen decreases expression EXP Sirolimus results in decreased expression of CD86 protein CTD PMID:12531798 NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443 		JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA CTD PMID:19016759 NCBI chr 4:118,290,098...118,294,540
Ensembl chr 4:118,290,098...118,294,549 		JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions		 ISO Sirolimus results in increased expression of CDH1 protein
Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]		 CTD PMID:28624451 PMID:28888487 PMID:30053495 NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] CTD PMID:30053495 NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303 		JBrowse link
G Cdk1 cyclin dependent kinase 1 multiple interactions
decreases expression
decreases activity		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein; [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA
Sirolimus results in decreased expression of CDK1
Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]
Sirolimus results in decreased activity of CDK1 protein
Sirolimus results in decreased expression of CDK1 mRNA; Sirolimus results in decreased expression of CDK1 protein		 CTD PMID:7503980 PMID:7532117 PMID:8419408 PMID:11355896 PMID:15767555 More... NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity		 ISO
EXP		 [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein
Sirolimus results in decreased activity of CDK2 protein
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]		 CTD PMID:7532117 PMID:12393642 PMID:12417722 PMID:14979923 PMID:21528311 NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900 		JBrowse link
G Cdk4 cyclin dependent kinase 4 decreases expression ISO Sirolimus results in decreased expression of CDK4 protein CTD PMID:22761470 NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789 		JBrowse link
G Cdkn1a cyclin dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression		 ISO
EXP		 [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A mRNA; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA]; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A mRNA]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA]
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
Sirolimus results in increased expression of CDKN1A mRNA; Sirolimus results in increased expression of CDKN1A protein
Sirolimus results in decreased expression of CDKN1A protein
Sirolimus inhibits the reaction [arsenite results in increased expression of CDKN1A protein]		 CTD PMID:12417722 PMID:14979923 PMID:17700525 PMID:19105244 PMID:19764996 More... NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701 		JBrowse link
G Cdkn1b cyclin dependent kinase inhibitor 1B multiple interactions
decreases degradation
increases expression
decreases expression		 ISO
EXP		 [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA]
Sirolimus results in decreased degradation of CDKN1B protein
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
Sirolimus results in increased expression of CDKN1B protein
Sirolimus results in decreased expression of CDKN1B protein		 CTD PMID:12417722 PMID:12565877 PMID:14979923 PMID:15070696 PMID:16455087 More... NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476 		JBrowse link
G Cdx2 caudal type homeobox 2 increases expression EXP Sirolimus results in increased expression of CDX2 mRNA CTD PMID:21681844 NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha decreases expression EXP Sirolimus results in decreased expression of CEBPA mRNA CTD PMID:15358118 NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions EXP Sirolimus inhibits the reaction [Endrin results in increased expression of CEBPD mRNA] CTD PMID:34801515 NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895 		JBrowse link
G Cenpx centromere protein X increases expression EXP Sirolimus results in increased expression of CENPX mRNA CTD PMID:11355896 NCBI chr11:120,601,768...120,604,721
Ensembl chr11:120,601,768...120,604,564 		JBrowse link
G Cfd complement factor D decreases expression EXP Sirolimus results in decreased expression of CFD mRNA CTD PMID:15358118 NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489 		JBrowse link
G Chrnb3 cholinergic receptor, nicotinic, beta polypeptide 3 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] CTD PMID:21245298 NCBI chr 8:27,858,688...27,889,758
Ensembl chr 8:27,858,739...27,889,758 		JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions EXP Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] CTD PMID:31499194 NCBI chr 6:113,401,595...113,412,721
Ensembl chr 6:113,401,595...113,412,721 		JBrowse link
G Cks1b CDC28 protein kinase 1b decreases expression EXP Sirolimus results in decreased expression of CKS1B mRNA CTD PMID:11355896 NCBI chr 3:89,322,779...89,325,598
Ensembl chr 3:89,322,779...89,325,690 		JBrowse link
G Cldn7 claudin 7 increases expression ISO Sirolimus results in increased expression of CLDN7 mRNA CTD PMID:21865292 NCBI chr11:69,855,605...69,858,712
Ensembl chr11:69,855,605...69,858,711 		JBrowse link
G Clec4a3 C-type lectin domain family 4, member a3 decreases expression ISO Sirolimus results in decreased expression of CLEC4A mRNA CTD PMID:21865292 NCBI chr 6:122,929,474...122,946,837
Ensembl chr 6:122,929,474...122,946,834 		JBrowse link
G Cluh clustered mitochondria homolog increases expression ISO Sirolimus results in increased expression of CLUH protein CTD PMID:36214828 NCBI chr11:74,539,707...74,561,680
Ensembl chr11:74,540,321...74,561,673 		JBrowse link
G Col1a1 collagen, type I, alpha 1 decreases expression
multiple interactions		 ISO
EXP		 Sirolimus results in decreased expression of COL1A1 mRNA
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]		 CTD PMID:21865292 PMID:35405287 NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868 		JBrowse link
G Col1a2 collagen, type I, alpha 2 multiple interactions ISO Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA]
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]		 CTD PMID:10535884 PMID:11343241 NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544 		JBrowse link
G Col2a1 collagen, type II, alpha 1 decreases expression EXP Sirolimus results in decreased expression of COL2A1 protein CTD PMID:34536393 NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576 		JBrowse link
G Cp ceruloplasmin increases expression ISO Sirolimus results in increased expression of CP mRNA CTD PMID:21865292 NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309 		JBrowse link
G Cpt1b carnitine palmitoyltransferase 1b, muscle multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]] CTD PMID:25045214 NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066 		JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]] CTD PMID:25045214 NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]] CTD PMID:22363816 NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707 		JBrowse link
G Crebrf CREB3 regulatory factor multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CREBRF mRNA CTD PMID:25307878 NCBI chr17:26,918,716...26,995,611
Ensembl chr17:26,934,624...26,995,609 		JBrowse link
G Crtc2 CREB regulated transcription coactivator 2 decreases activity ISO Sirolimus results in decreased activity of CRTC2 protein CTD PMID:23440206 NCBI chr 3:90,161,475...90,171,432
Ensembl chr 3:90,161,470...90,171,432 		JBrowse link
G Cs citrate synthase multiple interactions EXP Sirolimus affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein] CTD PMID:33684387 NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348 		JBrowse link
G Cse1l chromosome segregation 1 like decreases expression EXP Sirolimus results in decreased expression of CSE1L mRNA CTD PMID:11355896 NCBI chr 2:166,747,961...166,788,309
Ensembl chr 2:166,747,960...166,788,309 		JBrowse link
G Csf1 colony stimulating factor 1 (macrophage) multiple interactions EXP Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785 		JBrowse link
G Csf2 colony stimulating factor 2 (granulocyte-macrophage) multiple interactions EXP Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]] CTD PMID:1376361 NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] CTD PMID:30053495 NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573 		JBrowse link
G Ctsk cathepsin K multiple interactions
decreases expression		 EXP PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased activity of CTSK protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]
Sirolimus results in decreased expression of CTSK mRNA		 CTD PMID:26369790 NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases expression ISO Sirolimus results in decreased expression of CXCL10 mRNA CTD PMID:21865292 NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression ISO Sirolimus results in decreased expression of CXCL13 mRNA CTD PMID:21865292 NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927 		JBrowse link
G Cxcl15 C-X-C motif chemokine ligand 15 multiple interactions
increases expression		 ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CXCL8 mRNA; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]
Sirolimus results in increased expression of CXCL8 mRNA		 CTD PMID:17606477 PMID:25307878 PMID:27542212 PMID:29594315 NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926 		JBrowse link
G Cyba cytochrome b-245, alpha polypeptide multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] CTD PMID:21195169 NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669 		JBrowse link
G Cybb cytochrome b-245, beta polypeptide multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] CTD PMID:21195169 NCBI chr  X:9,301,493...9,354,005
Ensembl chr  X:9,301,491...9,354,010 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Sirolimus results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490 		JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions
decreases activity		 ISO [Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein
Sirolimus results in decreased activity of CYP27A1 protein		 CTD PMID:17516993 NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051 		JBrowse link
G Cyp2a5 cytochrome P450, family 2, subfamily a, polypeptide 5 decreases expression ISO Sirolimus results in decreased expression of CYP2A6 protein CTD PMID:25929522 NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973 		JBrowse link
G Cyp2b10 cytochrome P450, family 2, subfamily b, polypeptide 10 increases expression ISO Sirolimus results in increased expression of CYP2B6 mRNA CTD PMID:25929522 NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049 		JBrowse link
G Cyp2c65 cytochrome P450, family 2, subfamily c, polypeptide 65 increases expression
decreases expression		 ISO Sirolimus results in increased expression of CYP2C9 mRNA
Sirolimus results in decreased expression of CYP2C9 protein		 CTD PMID:25929522 NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Sirolimus affects the reaction [FXN protein affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol]] CTD PMID:33017621 NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP
ISO		 Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of DDIT3 protein]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of DDIT3 mRNA; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA]; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [honokiol results in increased expression of DDIT3 protein]		 CTD PMID:11145585 PMID:19420259 PMID:21321189 PMID:22215663 PMID:25307878 More... NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157
Ensembl chr10:127,126,643...127,132,157 		JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like increases expression
decreases expression		 ISO Sirolimus results in increased expression of DDIT4L mRNA
Sirolimus results in decreased expression of DDIT4L mRNA		 CTD PMID:21865292 NCBI chr 3:137,329,433...137,334,093
Ensembl chr 3:137,327,373...137,334,094 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA] CTD PMID:21245298 NCBI chr15:54,975,824...55,122,667
Ensembl chr15:54,975,713...55,122,667 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] CTD PMID:15767555 NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239 		JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions EXP Sirolimus inhibits the reaction [Ketamine results in increased expression of DLG4 protein] CTD PMID:33022268 NCBI chr11:69,908,029...69,938,107
Ensembl chr11:69,907,768...69,938,348 		JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 decreases expression ISO Sirolimus results in decreased expression of DNAJC6 mRNA CTD PMID:21865292 NCBI chr 4:101,353,751...101,499,996
Ensembl chr 4:101,353,828...101,499,996 		JBrowse link
G Dnm1l dynamin 1-like multiple interactions EXP Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of DNM1L protein] CTD PMID:35405287 NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823 		JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA CTD PMID:19016759 NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184 		JBrowse link
G Dpyd dihydropyrimidine dehydrogenase decreases expression ISO Sirolimus results in decreased expression of DPYD mRNA CTD PMID:19764996 NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573 		JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression ISO Sirolimus results in increased expression of DUSP10 mRNA CTD PMID:24356939 NCBI chr 1:183,766,575...183,807,833
Ensembl chr 1:183,745,499...183,807,833 		JBrowse link
G Dusp15 dual specificity phosphatase-like 15 decreases expression ISO Sirolimus results in decreased expression of DUSP15 mRNA CTD PMID:21865292 NCBI chr 2:152,782,915...152,794,200
Ensembl chr 2:152,782,917...152,793,618 		JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO
EXP		 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein CTD PMID:12417722 NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812 		JBrowse link
G E2f4 E2F transcription factor 4 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr 8:106,024,295...106,032,002
Ensembl chr 8:106,024,295...106,032,002 		JBrowse link
G Edn1 endothelin 1 multiple interactions ISO Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:12411397 NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466 		JBrowse link
G Eef2 eukaryotic translation elongation factor 2 increases phosphorylation ISO Sirolimus results in increased phosphorylation of EEF2 protein CTD PMID:25940091 NCBI chr10:81,012,465...81,018,343
Ensembl chr10:81,012,465...81,018,332 		JBrowse link
G Egf epidermal growth factor multiple interactions
decreases activity		 ISO
EXP		 Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]
Sirolimus analog results in decreased activity of EGF protein		 CTD PMID:12406821 PMID:21187475 NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions EXP
ISO		 [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]; Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein CTD PMID:19151764 NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha multiple interactions ISO Sirolimus inhibits the reaction [cadmium acetate results in increased phosphorylation of EIF2S1 protein] CTD PMID:29870746 NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784 		JBrowse link
G Eif4b eukaryotic translation initiation factor 4B multiple interactions
decreases phosphorylation		 EXP
ISO		 [resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of EIF4B protein; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of EIF4B protein
Sirolimus results in decreased phosphorylation of EIF4B protein		 CTD PMID:21268130 PMID:24304514 PMID:24375594 NCBI chr15:101,982,208...102,005,608
Ensembl chr15:101,982,208...102,005,608 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases activity
increases phosphorylation
increases expression		 ISO
EXP		 EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]
Sirolimus results in decreased activity of EIF4E protein
Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4E protein]
Sirolimus results in increased phosphorylation of EIF4E protein
Sirolimus results in increased expression of EIF4E mRNA		 CTD PMID:15757502 PMID:19560264 PMID:26282490 PMID:34453960 NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
decreases phosphorylation
affects phosphorylation		 ISO
EXP		 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Oxygen deficiency] results in increased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]
Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Polystyrenes analog results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein; Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein]
Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4EBP1 protein]
Sirolimus affects the phosphorylation of EIF4EBP1 protein		 CTD PMID:8599949 PMID:8971030 PMID:11909977 PMID:12411397 PMID:12939469 More... NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702 		JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4, gamma 1 multiple interactions ISO Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA] CTD PMID:25940091 NCBI chr16:20,491,457...20,511,633
Ensembl chr16:20,487,063...20,511,634 		JBrowse link
G Eif4g2 eukaryotic translation initiation factor 4, gamma 2 increases expression ISO Sirolimus results in increased expression of EIF4G2 protein CTD PMID:18491231 NCBI chr 7:110,667,192...110,682,237
Ensembl chr 7:110,666,957...110,682,237 		JBrowse link
G Eno2 enolase 2, gamma neuronal increases expression
multiple interactions		 ISO Sirolimus results in increased expression of ENO2 protein
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]		 CTD PMID:26676567 NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signalling 1 multiple interactions EXP
ISO		 [Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]
Sirolimus inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]		 CTD PMID:24898257 PMID:32283200 NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678 		JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha multiple interactions ISO Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] CTD PMID:19420259 NCBI chr14:45,520,544...45,556,029
Ensembl chr14:45,520,544...45,556,228 		JBrowse link
G Espl1 extra spindle pole bodies 1, separase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA CTD PMID:19016759 NCBI chr15:102,204,688...102,232,792
Ensembl chr15:102,204,701...102,232,792 		JBrowse link
G Esr1 estrogen receptor 1 (alpha) increases expression
increases phosphorylation		 ISO Sirolimus results in increased expression of ESR1 protein
Sirolimus results in increased phosphorylation of ESR1 protein		 CTD PMID:19016759 NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614 		JBrowse link
G Evi2a ecotropic viral integration site 2a increases expression ISO Sirolimus results in increased expression of EVI2A mRNA CTD PMID:24356939 NCBI chr11:79,417,386...79,421,435
Ensembl chr11:79,417,386...79,421,435 		JBrowse link
G Ewsr1 Ewing sarcoma breakpoint region 1 decreases expression ISO Sirolimus results in decreased expression of EWSR1 protein mutant form CTD PMID:15782132 NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266 		JBrowse link
G F2 coagulation factor II decreases expression ISO Sirolimus results in decreased expression of F2 mRNA CTD PMID:21865292 NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759 		JBrowse link
G F3 coagulation factor III multiple interactions
increases activity		 ISO
EXP		 Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus results in increased activity of F3 protein		 CTD PMID:19567381 NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697 		JBrowse link
G Fas Fas cell surface death receptor decreases expression EXP Sirolimus results in decreased expression of FAS mRNA CTD PMID:15358118 NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172 		JBrowse link
G Fasl Fas ligand decreases secretion ISO Sirolimus results in decreased secretion of FASLG protein CTD PMID:11692113 NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064 		JBrowse link
G Faxdc2 fatty acid hydroxylase domain containing 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] CTD PMID:21245298 NCBI chr11:57,954,508...57,983,977
Ensembl chr11:57,954,378...57,983,960 		JBrowse link
G Fbln1 fibulin 1 increases expression ISO Sirolimus results in increased expression of FBLN1 mRNA CTD PMID:21865292 NCBI chr15:85,090,150...85,170,495
Ensembl chr15:85,090,150...85,170,736 		JBrowse link
G Fbxo32 F-box protein 32 multiple interactions
increases expression		 ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of FBXO32 mRNA; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]
Sirolimus results in increased expression of FBXO32 mRNA		 CTD PMID:21245298 PMID:24356939 PMID:25307878 NCBI chr15:58,039,275...58,078,288
Ensembl chr15:58,039,275...58,078,328 		JBrowse link
G Fbxo5 F-box protein 5 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA CTD PMID:19016759 NCBI chr10:5,749,155...5,755,465
Ensembl chr10:5,749,160...5,755,600 		JBrowse link
G Fcgr1 Fc receptor, IgG, high affinity I multiple interactions
decreases expression		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Sirolimus results in decreased expression of FCGR1A protein]; arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein] CTD PMID:25758096 NCBI chr 3:96,190,225...96,201,285
Ensembl chr 3:96,190,225...96,201,285 		JBrowse link
G Fgb fibrinogen beta chain decreases expression
increases expression		 ISO Sirolimus results in decreased expression of FGB mRNA
Sirolimus results in increased expression of FGB mRNA		 CTD PMID:21865292 NCBI chr 3:82,949,553...82,957,170
Ensembl chr 3:82,947,448...82,957,170 		JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions ISO [Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of FGF1 mRNA; Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 PMID:31332898 NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525 		JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions EXP Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of FGF21 mRNA] CTD PMID:31499194 NCBI chr 7:45,263,314...45,264,914
Ensembl chr 7:45,263,310...45,264,914 		JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] CTD PMID:21245298 NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105 		JBrowse link
G Fkbp1a FK506 binding protein 1a affects binding
multiple interactions		 ISO
EXP		 Sirolimus binds to FKBP1A protein
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein; [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA; immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein]		 CTD PMID:7503980 PMID:7532117 PMID:10361256 PMID:12417722 PMID:12531798 More... NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612 		JBrowse link
G Flt3l FMS-like tyrosine kinase 3 ligand decreases activity EXP Sirolimus results in decreased activity of FLT3LG protein CTD PMID:12531798 NCBI chr 7:44,780,607...44,785,914
Ensembl chr 7:44,779,212...44,785,856 		JBrowse link
G Folr1 folate receptor alpha multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] CTD PMID:21245298 NCBI chr 7:101,507,551...101,519,974
Ensembl chr 7:101,507,538...101,519,995 		JBrowse link
G Foxm1 forkhead box M1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA CTD PMID:19016759 NCBI chr 6:128,339,957...128,352,849
Ensembl chr 6:128,339,930...128,353,109 		JBrowse link
G Foxo1 forkhead box O1 increases phosphorylation ISO Sirolimus results in increased phosphorylation of FOXO1 protein CTD PMID:16227402 NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions
increases phosphorylation		 ISO [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3 protein]; Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3 protein CTD PMID:21092744 NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751 		JBrowse link
G Foxp1 forkhead box P1 decreases expression ISO Sirolimus results in decreased expression of FOXP1 protein CTD PMID:25663935 NCBI chr 6:98,902,303...99,510,587
Ensembl chr 6:98,902,299...99,499,682 		JBrowse link
G Foxp3 forkhead box P3 multiple interactions
increases expression		 ISO
EXP		 [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
Sirolimus results in increased expression of FOXP3 mRNA		 CTD PMID:20844194 NCBI chr  X:7,445,915...7,461,482
Ensembl chr  X:7,439,883...7,461,484 		JBrowse link
G Frat1 frequently rearranged in advanced T cell lymphomas increases expression ISO Sirolimus results in increased expression of FRAT1 mRNA CTD PMID:24356939 NCBI chr19:41,818,409...41,821,022
Ensembl chr19:41,818,409...41,821,022 		JBrowse link
G Fshb follicle stimulating hormone beta multiple interactions ISO Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] CTD PMID:17510244 NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001 		JBrowse link
G Ftl1 ferritin light polypeptide 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] CTD PMID:21245298 NCBI chr 7:45,107,368...45,109,310
Ensembl chr 7:45,107,368...45,109,308 		JBrowse link
G Fxn frataxin multiple interactions ISO Sirolimus affects the reaction [FXN protein affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol]] CTD PMID:33017621 NCBI chr19:24,236,909...24,257,954
Ensembl chr19:24,238,817...24,257,969 		JBrowse link
G Gabarap gamma-aminobutyric acid receptor associated protein increases expression EXP Sirolimus results in increased expression of GABARAP mRNA CTD PMID:21681844 NCBI chr11:69,882,196...69,885,775
Ensembl chr11:69,881,969...69,885,777 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 multiple interactions EXP Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein CTD PMID:15888080 NCBI chr 6:129,510,155...129,519,294
Ensembl chr 6:129,510,123...129,519,309 		JBrowse link
G Gcm2 glial cells missing homolog 2 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] CTD PMID:21245298 NCBI chr13:41,254,903...41,264,511
Ensembl chr13:41,254,903...41,264,511 		JBrowse link
G Gem GTP binding protein overexpressed in skeletal muscle multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of GEM mRNA CTD PMID:25307878 NCBI chr 4:11,702,379...11,714,993
Ensembl chr 4:11,704,457...11,714,752 		JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions ISO Sirolimus promotes the reaction [Cyclosporine affects the expression of GGT1 protein] CTD PMID:11589784 NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034 		JBrowse link
G Gja1 gap junction protein, alpha 1 decreases expression ISO Sirolimus results in decreased expression of GJA1 protein CTD PMID:35750204 NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609 		JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
decreases expression		 ISO Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Sirolimus results in decreased expression of GLB1 protein		 CTD PMID:22561310 NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966 		JBrowse link
G Gm22728 predicted gene, 22728 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SCARNA23 mRNA CTD PMID:25307878 NCBI chr 5:92,203,923...92,204,051
Ensembl chr 5:92,203,923...92,204,051 		JBrowse link
G Gnai1 G protein subunit alpha i1 multiple interactions EXP Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI1 protein]] CTD PMID:29748632 NCBI chr 5:18,470,133...18,565,411
Ensembl chr 5:18,470,133...18,565,353 		JBrowse link
G Gnai3 G protein subunit alpha i3 multiple interactions EXP Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI3 protein]] CTD PMID:29748632 NCBI chr 3:108,014,591...108,053,468
Ensembl chr 3:108,014,596...108,053,462 		JBrowse link
G Gnaz guanine nucleotide binding protein, alpha z subunit multiple interactions EXP Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAZ protein]] CTD PMID:29748632 NCBI chr10:74,803,009...74,852,739
Ensembl chr10:74,803,009...74,852,739 		JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 multiple interactions ISO Sirolimus inhibits the reaction [puerarin results in increased expression of GPER1 protein] CTD PMID:27796870 NCBI chr 5:139,408,905...139,413,555
Ensembl chr 5:139,408,906...139,413,555 		JBrowse link
G Gpnmb glycoprotein (transmembrane) nmb increases expression ISO Sirolimus results in increased expression of GPNMB mRNA CTD PMID:21865292 NCBI chr 6:49,013,449...49,044,413
Ensembl chr 6:49,013,480...49,047,863 		JBrowse link
G Gpr18 G protein-coupled receptor 18 increases expression ISO Sirolimus results in increased expression of GPR18 mRNA CTD PMID:24356939 NCBI chr14:122,148,846...122,153,300
Ensembl chr14:122,148,665...122,153,193 		JBrowse link
G Gpt glutamic pyruvic transaminase, soluble multiple interactions ISO
EXP		 Sirolimus promotes the reaction [Cyclosporine affects the expression of GPT protein]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased activity of GPT protein]]		 CTD PMID:11589784 PMID:31499194 NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases activity		 ISO
EXP		 [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]		 CTD PMID:15753396 PMID:17908691 PMID:18495876 NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446 		JBrowse link
G Gstt1 glutathione S-transferase, theta 1 increases response to substance ISO GSTT1 gene mutant form results in increased susceptibility to Sirolimus CTD PMID:12916871 NCBI chr10:75,619,647...75,634,418
Ensembl chr10:75,619,647...75,634,418 		JBrowse link
G Gtpbp4 GTP binding protein 4 decreases expression ISO Sirolimus results in decreased expression of GTPBP4 mRNA CTD PMID:21865292 NCBI chr13:9,016,039...9,046,080
Ensembl chr13:9,016,367...9,046,119 		JBrowse link
G Guca2a guanylate cyclase activator 2a (guanylin) increases expression ISO Sirolimus results in increased expression of GUCA2A mRNA CTD PMID:21865292 NCBI chr 4:119,494,929...119,496,662
Ensembl chr 4:119,494,901...119,496,668 		JBrowse link
G Gzmb granzyme B decreases expression ISO Sirolimus results in decreased expression of GZMB protein CTD PMID:16477233 NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717 		JBrowse link
G H2ax H2A.X variant histone decreases expression ISO Sirolimus results in decreased expression of H2AX protein CTD PMID:23363784 NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 increases expression ISO Sirolimus results in increased expression of HAVCR1 mRNA CTD PMID:21865292 NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405 		JBrowse link
G Hbp1 high mobility group box transcription factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of HBP1 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] CTD PMID:25307878 PMID:27542212 NCBI chr12:31,976,449...32,000,529
Ensembl chr12:31,976,253...32,000,534 		JBrowse link
G Hes1 hes family bHLH transcription factor 1 decreases expression ISO
EXP		 Sirolimus results in decreased expression of HES1 protein
Sirolimus results in decreased expression of HES1 mRNA; Sirolimus results in decreased expression of HES1 protein		 CTD PMID:20038814 NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614 		JBrowse link
G Hif1a hypoxia inducible factor 1, alpha subunit multiple interactions
decreases expression		 ISO
EXP		 [Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Oxygen deficiency inhibits the reaction [Sirolimus inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein]
Sirolimus results in decreased expression of HIF1A protein
Sirolimus results in decreased expression of HIF1A mRNA
Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein]		 CTD PMID:15050414 PMID:15297429 PMID:15634505 PMID:16682453 PMID:17968710 More... NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304 		JBrowse link
G Hk2 hexokinase 2 multiple interactions
decreases expression		 ISO Curcumin promotes the reaction [Sirolimus results in decreased expression of HK2 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of HK2 protein] CTD PMID:36336208 PMID:36640941 NCBI chr 6:82,702,004...82,751,437
Ensembl chr 6:82,702,006...82,751,435 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase increases expression ISO Sirolimus results in increased expression of HMGCR mRNA CTD PMID:17516993 NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 EXP
ISO		 Sirolimus results in increased expression of HMOX1
Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]		 CTD PMID:17003813 PMID:19420259 NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217 		JBrowse link
G Hnrnpd heterogeneous nuclear ribonucleoprotein D decreases expression
increases expression		 ISO Sirolimus results in decreased expression of HNRNPD protein
Sirolimus results in increased expression of HNRNPD protein		 CTD PMID:17603996 NCBI chr 5:100,103,794...100,126,926
Ensembl chr 5:100,103,794...100,126,797 		JBrowse link
G Hoxa9 homeobox A9 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] CTD PMID:21245298 NCBI chr 6:52,200,077...52,203,169
Ensembl chr 6:52,200,080...52,208,069 		JBrowse link
G Hras Harvey rat sarcoma virus oncogene multiple interactions EXP
ISO		 [Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR193A-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]		 CTD PMID:24898257 PMID:30619488 NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918 		JBrowse link
G Hsf1 heat shock factor 1 increases activity ISO Sirolimus results in increased activity of HSF1 protein CTD PMID:34170685 NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113 		JBrowse link
G Hspa1b heat shock protein 1B decreases expression ISO Sirolimus results in decreased expression of HSPA1B mRNA CTD PMID:24356939 NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214 		JBrowse link
G Hspa5 heat shock protein 5 decreases expression
multiple interactions		 ISO
EXP		 Sirolimus results in decreased expression of HSPA5 mRNA
[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein]		 CTD PMID:24356939 PMID:24898257 PMID:29870746 NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559 		JBrowse link
G Hspb8 heat shock protein 8 decreases expression ISO Sirolimus results in decreased expression of HSPB8 protein CTD PMID:21233418 NCBI chr 5:116,546,550...116,560,923
Ensembl chr 5:116,546,550...116,560,923 		JBrowse link
G Ibsp integrin binding sialoprotein multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] CTD PMID:31051157 NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335 		JBrowse link
G Icam1 intercellular adhesion molecule 1 decreases expression EXP Sirolimus results in decreased expression of ICAM1 protein CTD PMID:12531798 NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113 		JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression ISO Sirolimus results in increased expression of ID1 mRNA CTD PMID:23824090 PMID:24356939 NCBI chr 2:152,578,171...152,579,330
Ensembl chr 2:152,578,171...152,579,330 		JBrowse link
G Ifng interferon gamma multiple interactions
decreases secretion		 ISO
EXP		 Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
Sirolimus results in decreased secretion of IFNG protein
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]		 CTD PMID:11692113 PMID:16427044 PMID:21600178 NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions
increases response to substance		 ISO
EXP		 [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]
Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]
Sirolimus results in increased susceptibility to IGF1 protein
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]		 CTD PMID:11355896 PMID:15070696 PMID:15297429 PMID:16227402 PMID:16682453 More... NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904 		JBrowse link
G Igf1r insulin-like growth factor I receptor affects activity
multiple interactions		 ISO Sirolimus affects the activity of IGF1R protein
Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]		 CTD PMID:16227402 NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Sirolimus results in increased expression of IGFBP1 mRNA CTD PMID:21865292 NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] CTD PMID:16682453 NCBI chr11:7,156,086...7,165,498
Ensembl chr11:7,156,086...7,163,923 		JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression ISO Sirolimus results in decreased expression of IGFBP5 mRNA CTD PMID:21865292 NCBI chr 1:72,897,224...72,914,024
Ensembl chr 1:72,897,091...72,914,043 		JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression		 ISO
EXP		 Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein]
[Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]]
Sirolimus results in decreased expression of IL10 protein
Sirolimus results in decreased expression of IL10 mRNA		 CTD PMID:11169223 PMID:15588918 PMID:31499194 NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711 		JBrowse link
G Il12a interleukin 12a multiple interactions EXP Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880 		JBrowse link
G Il12b interleukin 12b multiple interactions EXP Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860 		JBrowse link
G Il17a interleukin 17A multiple interactions EXP Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of IL17A protein] CTD PMID:36849104 NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720 		JBrowse link
G Il17rb interleukin 17 receptor B multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA CTD PMID:19016759 NCBI chr14:29,718,125...29,730,853
Ensembl chr14:29,718,092...29,730,853 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] CTD PMID:30205151 NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
affects expression
increases expression		 EXP
ISO		 [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of IL1B protein]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of IL1B mRNA]
Sirolimus affects the expression of IL1B mRNA
Sirolimus results in increased expression of IL1B protein
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]
Sirolimus results in increased expression of IL1B mRNA
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]		 CTD PMID:22363816 PMID:23211629 PMID:24971338 PMID:25045214 PMID:29594315 More... NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059 		JBrowse link
G Il2 interleukin 2 multiple interactions
decreases response to substance
affects expression		 ISO
EXP		 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]
Sirolimus results in decreased susceptibility to IL2 protein
[Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
Sirolimus affects the expression of IL2 protein
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]		 CTD PMID:1614535 PMID:10373522 PMID:11355896 PMID:15588918 PMID:15778701 More... NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108 		JBrowse link
G Il2ra interleukin 2 receptor, alpha chain multiple interactions ISO Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] CTD PMID:8586487 NCBI chr 2:11,647,603...11,698,005
Ensembl chr 2:11,647,618...11,698,004 		JBrowse link
G Il2rg interleukin 2 receptor, gamma chain multiple interactions EXP [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein CTD PMID:12531798 NCBI chr  X:100,307,991...100,311,861
Ensembl chr  X:100,307,984...100,311,861 		JBrowse link
G Il3 interleukin 3 multiple interactions EXP Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]] CTD PMID:1376361 NCBI chr11:54,155,911...54,158,105
Ensembl chr11:54,156,129...54,158,103 		JBrowse link
G Il4 interleukin 4 multiple interactions
decreases expression		 EXP [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]]
Sirolimus analog results in decreased expression of IL4 protein; Sirolimus results in decreased expression of IL4 protein		 CTD PMID:12406821 PMID:12531798 PMID:15588918 NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496 		JBrowse link
G Il4ra interleukin 4 receptor, alpha multiple interactions EXP [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein CTD PMID:12531798 NCBI chr 7:125,151,443...125,178,646
Ensembl chr 7:125,151,292...125,178,646 		JBrowse link
G Il5 interleukin 5 decreases expression EXP Sirolimus analog results in decreased expression of IL5 protein CTD PMID:12406821 NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933 		JBrowse link
G Il6 interleukin 6 multiple interactions
decreases expression
increases expression		 ISO
EXP		 [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein
Sirolimus results in decreased expression of IL6 mRNA
Sirolimus results in increased expression of IL6
Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased expression of IL6 mRNA]		 CTD PMID:15070696 PMID:16314788 PMID:20844194 PMID:33823232 NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979 		JBrowse link
G Ing4 inhibitor of growth family, member 4 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] CTD PMID:21245298 NCBI chr 6:125,016,811...125,026,228
Ensembl chr 6:125,016,723...125,026,228 		JBrowse link
G Ins1 insulin I multiple interactions
decreases expression		 EXP
ISO		 Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]
Sirolimus results in decreased expression of INS1 protein
Sirolimus inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]
Sirolimus inhibits the reaction [Carbachol results in increased secretion of INS1 protein]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]		 CTD PMID:14578291 PMID:20880397 PMID:21357504 PMID:23920219 PMID:26563389 More... NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914 		JBrowse link
G Ins2 insulin II multiple interactions ISO Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein] CTD PMID:20936651 PMID:28790194 PMID:28984034 NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118 		JBrowse link
G Insig1 insulin induced gene 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of INSIG1 mRNA CTD PMID:25307878 NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660 		JBrowse link
G Irs1 insulin receptor substrate 1 affects phosphorylation
multiple interactions
decreases degradation
decreases phosphorylation		 ISO Sirolimus affects the phosphorylation of IRS1 protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein]
Sirolimus results in decreased degradation of IRS1 protein
Sirolimus results in decreased phosphorylation of IRS1 protein		 CTD PMID:16227402 PMID:17908691 PMID:20936651 PMID:28984034 NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137 		JBrowse link
G Itgam integrin alpha M multiple interactions
increases expression		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein]; [Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein; Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein]
Sirolimus results in increased expression of ITGAM protein		 CTD PMID:20574048 PMID:25758096 NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663 		JBrowse link
G Itgav integrin alpha V decreases expression EXP Sirolimus results in decreased expression of ITGAV mRNA; Sirolimus results in decreased expression of ITGAV protein CTD PMID:19922502 NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260 		JBrowse link
G Jag1 jagged 1 decreases expression ISO
EXP		 Sirolimus results in decreased expression of JAG1 protein CTD PMID:20038814 NCBI chr 2:136,923,371...136,958,440
Ensembl chr 2:136,923,376...136,958,564 		JBrowse link
G Jmy junction-mediating and regulatory protein multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] CTD PMID:21245298 NCBI chr13:93,566,605...93,636,316
Ensembl chr13:93,566,609...93,636,316 		JBrowse link
G Jun jun proto-oncogene multiple interactions EXP Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of JUN protein] CTD PMID:26369790 NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459 		JBrowse link
G Keap1 kelch-like ECH-associated protein 1 multiple interactions
increases expression		 ISO Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [Particulate Matter affects the expression of KEAP1 protein]]
Sirolimus results in increased expression of KEAP1 protein		 CTD PMID:29781141 NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657 		JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression ISO Sirolimus results in increased expression of KIFAP3 mRNA CTD PMID:21865292 NCBI chr 1:163,589,711...163,744,676
Ensembl chr 1:163,607,152...163,744,678 		JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Sirolimus results in decreased expression of KIFC1 mRNA CTD PMID:21865292 NCBI chr17:34,094,640...34,109,607
Ensembl chr17:34,094,633...34,109,635 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions ISO KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16597595 NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382 		JBrowse link
G Kitl kit ligand multiple interactions EXP Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] CTD PMID:10849422 NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278 		JBrowse link
G Klf2 Kruppel-like transcription factor 2 (lung) increases expression ISO Sirolimus results in increased expression of KLF2 mRNA CTD PMID:24356939 NCBI chr 8:73,072,906...73,075,498
Ensembl chr 8:73,072,877...73,075,500 		JBrowse link
G Klf5 Kruppel-like transcription factor 5 increases expression ISO Sirolimus results in increased expression of KLF5 mRNA CTD PMID:21865292 NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472 		JBrowse link
G Klf6 Kruppel-like transcription factor 6 decreases phosphorylation EXP Sirolimus results in decreased phosphorylation of KLF6 protein CTD PMID:16611854 NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393 		JBrowse link
G Klhl24 kelch-like 24 increases expression
multiple interactions		 ISO Sirolimus results in increased expression of KLHL24 mRNA
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of KLHL24 mRNA		 CTD PMID:24356939 PMID:25307878 NCBI chr16:19,916,286...19,947,976
Ensembl chr16:19,916,292...19,947,971 		JBrowse link
G L1cam L1 cell adhesion molecule affects response to substance ISO L1CAM affects the susceptibility to Sirolimus CTD PMID:21097529 NCBI chr  X:72,897,384...72,924,843
Ensembl chr  X:72,897,384...72,939,711 		JBrowse link
G Lamc2 laminin, gamma 2 increases expression ISO Sirolimus results in increased expression of LAMC2 mRNA CTD PMID:21865292 NCBI chr 1:152,998,502...153,062,193
Ensembl chr 1:152,998,502...153,062,193 		JBrowse link
G Larp1 La ribonucleoprotein 1, translational regulator multiple interactions
increases response to substance		 ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]
LARP1 protein results in increased susceptibility to Sirolimus		 CTD PMID:25940091 NCBI chr11:57,899,711...57,952,860
Ensembl chr11:57,899,890...57,952,860 		JBrowse link
G Lat2 linker for activation of T cells family, member 2 increases response to substance ISO LAT2 protein results in increased susceptibility to Sirolimus CTD PMID:32587277 NCBI chr 5:134,628,957...134,648,637
Ensembl chr 5:134,628,876...134,643,879 		JBrowse link
G Lcn2 lipocalin 2 increases expression ISO Sirolimus results in increased expression of LCN2 mRNA CTD PMID:21865292 NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264 		JBrowse link
G Ldha lactate dehydrogenase A multiple interactions
increases expression		 ISO Curcumin inhibits the reaction [Sirolimus results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of LDHA protein] CTD PMID:36336208 PMID:36640941 NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051 		JBrowse link
G Lif leukemia inhibitory factor multiple interactions EXP Sirolimus promotes the reaction [cypermethrin results in decreased expression of LIF protein] CTD PMID:37011868 NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514 		JBrowse link
G Lipe lipase, hormone sensitive multiple interactions EXP Sirolimus promotes the reaction [Isoproterenol results in increased phosphorylation of LIPE protein] CTD PMID:21042876 NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135 		JBrowse link
G Lmnb1 lamin B1 multiple interactions ISO Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of and affects the localization of LMNB1 protein] CTD PMID:38604309 NCBI chr18:56,840,885...56,886,496
Ensembl chr18:56,840,885...56,886,496 		JBrowse link
G Mad2l1 MAD2 mitotic arrest deficient-like 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA CTD PMID:19016759 NCBI chr 6:66,512,205...66,518,091
Ensembl chr 6:66,512,374...66,524,204 		JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; Sirolimus results in increased expression of and results in decreased phosphorylation of MAF1 protein CTD PMID:31645432 NCBI chr15:76,235,494...76,238,578
Ensembl chr15:76,235,494...76,238,580 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions ISO [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form CTD PMID:21742779 NCBI chr 2:155,118,284...155,119,993
Ensembl chr 2:155,118,217...155,119,993 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
affects localization
multiple interactions
affects metabolic processing
increases lipidation		 ISO
EXP		 Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein; Sirolimus results in increased expression of MAP1LC3B protein modified form
Sirolimus affects the localization of MAP1LC3B protein
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; saikosaponin D inhibits the reaction [Sirolimus results in increased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [saikosaponin D results in decreased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Sirolimus results in increased expression of and results in increased cleavage of MAP1LC3B protein
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein modified form
Sirolimus affects the metabolism of MAP1LC3B protein
CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]; Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Ethanol results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein]
[bisphenol A co-treated with Sirolimus] results in increased lipidation of MAP1LC3B protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; PRKD2 protein affects the reaction [Sirolimus results in increased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [honokiol results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [hydroquinone results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]		 CTD PMID:18640276 PMID:19815708 PMID:21212465 PMID:21681844 PMID:23680031 More... NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499 		JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions
increases expression		 ISO 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] CTD PMID:26676567 NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742 		JBrowse link
G Map2k1 mitogen-activated protein kinase kinase 1 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein
Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]		 CTD PMID:12411397 PMID:15767555 NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913 		JBrowse link
G Map2k2 mitogen-activated protein kinase kinase 2 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein CTD PMID:15767555 NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809 		JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
decreases phosphorylation
increases phosphorylation
affects phosphorylation		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; arsenic trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]
Sirolimus results in decreased phosphorylation of MAPK1 protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]
Sirolimus affects the phosphorylation of MAPK1 protein		 CTD PMID:15767555 PMID:16255777 PMID:18374093 PMID:19151764 PMID:20936651 More... NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317 		JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
decreases phosphorylation
increases phosphorylation
affects phosphorylation		 ISO
EXP		 [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; arsenic trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]
Sirolimus results in decreased phosphorylation of MAPK3 protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]
Sirolimus affects the phosphorylation of MAPK3 protein		 CTD PMID:15767555 PMID:16255777 PMID:16391472 PMID:18374093 PMID:19151764 More... NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] CTD PMID:15767555 NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO Sirolimus results in decreased expression of and results in decreased cleavage of MAPT protein CTD PMID:33124469 NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916 		JBrowse link
G Mbnl2 muscleblind like splicing factor 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] CTD PMID:21245298 NCBI chr14:120,513,077...120,669,110
Ensembl chr14:120,513,081...120,669,109 		JBrowse link
G Mbp myelin basic protein increases expression EXP Sirolimus results in increased expression of MBP protein CTD PMID:20739560 NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762 		JBrowse link
G Mcl1 myeloid cell leukemia sequence 1 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased stability of and results in decreased ubiquitination of MCL1 protein] CTD PMID:15767555 PMID:25758096 PMID:32802178 NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487 		JBrowse link
G Mcm2 minichromosome maintenance complex component 2 multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA] CTD PMID:11355896 NCBI chr 6:88,860,456...88,875,762
Ensembl chr 6:88,860,456...88,875,762 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions EXP Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA] CTD PMID:11355896 NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684 		JBrowse link
G Mdm2 transformed mouse 3T3 cell double minute 2 multiple interactions
decreases expression		 ISO EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] CTD PMID:15625077 PMID:19560264 PMID:21245298 NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663 		JBrowse link
G Mir122 microRNA 122 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA] CTD PMID:23920219 NCBI chr18:65,381,932...65,381,997
Ensembl chr18:65,381,932...65,381,997 		JBrowse link
G Mir132 microRNA 132 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA] CTD PMID:23920219 NCBI chr11:75,064,508...75,064,573
Ensembl chr11:75,064,508...75,064,573 		JBrowse link
G Mir146 microRNA 146 multiple interactions ISO Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA] CTD PMID:30619488 NCBI chr11:43,265,224...43,265,288
Ensembl chr11:43,265,224...43,265,288 		JBrowse link
G Mir151 microRNA 151 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] CTD PMID:21245298 NCBI chr15:73,126,664...73,126,731
Ensembl chr15:73,126,664...73,126,731 		JBrowse link
G Mir181a-2 microRNA 181a-2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] CTD PMID:21245298 NCBI chr 2:38,742,747...38,742,822
Ensembl chr 2:38,742,747...38,742,822 		JBrowse link
G Mir190a microRNA 190a multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] CTD PMID:21245298 NCBI chr 9:67,143,942...67,144,008
Ensembl chr 9:67,143,942...67,144,008 		JBrowse link
G Mir212 microRNA 212 multiple interactions ISO Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA] CTD PMID:23920219 NCBI chr11:75,064,214...75,064,304
Ensembl chr11:75,064,214...75,064,304 		JBrowse link
G Mir29c microRNA 29c multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA] CTD PMID:21245298 NCBI chr 1:194,719,855...194,719,942
Ensembl chr 1:194,719,855...194,719,942 		JBrowse link
G Mir324 microRNA 324 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] CTD PMID:21245298 NCBI chr11:69,902,869...69,902,957
Ensembl chr11:69,902,869...69,902,957 		JBrowse link
G Mir330 microRNA 330 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MIR330 mRNA CTD PMID:25307878 NCBI chr 7:18,915,390...18,915,487
Ensembl chr 7:18,915,390...18,915,487 		JBrowse link
G Mir379 microRNA 379 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA] CTD PMID:21245298 NCBI chr12:109,675,494...109,675,559
Ensembl chr12:109,675,494...109,675,559 		JBrowse link
G Mir433 microRNA 433 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] CTD PMID:21245298 NCBI chr12:109,558,149...109,558,272
Ensembl chr12:109,558,149...109,558,272 		JBrowse link
G Mir503 microRNA 503 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] CTD PMID:21245298 NCBI chr  X:52,142,861...52,142,931
Ensembl chr  X:52,142,861...52,142,931 		JBrowse link
G Mir654 microRNA 654 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA] CTD PMID:21245298 NCBI chr12:109,689,652...109,689,735
Ensembl chr12:109,689,652...109,689,735 		JBrowse link
G Mir758 microRNA 758 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA] CTD PMID:21245298 NCBI chr12:109,679,244...109,679,324
Ensembl chr12:109,679,244...109,679,324 		JBrowse link
G Mir760 microRNA 760 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] CTD PMID:21245298 NCBI chr 3:122,087,234...122,087,352
Ensembl chr 3:122,087,234...122,087,352 		JBrowse link
G Mki67 antigen identified by monoclonal antibody Ki 67 decreases expression
multiple interactions
affects expression		 ISO Sirolimus results in decreased expression of MKI67 protein
[ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
Sirolimus affects the expression of MKI67 mRNA		 CTD PMID:19773376 PMID:24971338 NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090 		JBrowse link
G Mlst8 MTOR associated protein, LST8 homolog (S. cerevisiae) multiple interactions ISO Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] CTD PMID:19505958 NCBI chr17:24,692,524...24,698,722
Ensembl chr17:24,692,525...24,698,052 		JBrowse link
G Mmp1b matrix metallopeptidase 1b (interstitial collagenase) increases expression
increases secretion		 ISO Sirolimus results in increased expression of MMP1 mRNA
Sirolimus results in increased secretion of MMP1 protein		 CTD PMID:21742783 NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases expression		 ISO Sirolimus inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein]
Curcumin inhibits the reaction [Sirolimus results in increased expression of MMP2 protein]; Sirolimus inhibits the reaction [Chloroquine results in decreased expression of MMP2 protein]; Sirolimus inhibits the reaction [Hydroxychloroquine results in decreased expression of MMP2 protein]		 CTD PMID:17050028 PMID:34278709 PMID:36640941 NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048 		JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression
multiple interactions
increases expression		 ISO
EXP		 Sirolimus results in decreased expression of MMP9 mRNA
Sirolimus promotes the reaction [cypermethrin results in decreased expression of MMP9 protein]
Sirolimus results in increased expression of MMP9 protein
Curcumin inhibits the reaction [Sirolimus results in increased expression of MMP9 protein]		 CTD PMID:21865292 PMID:36640941 PMID:37011868 NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770 		JBrowse link
G Mpz myelin protein zero increases expression EXP Sirolimus results in increased expression of MPZ protein CTD PMID:20739560 NCBI chr 1:170,978,282...170,988,699
Ensembl chr 1:170,978,280...170,988,699 		JBrowse link
G Msr1 macrophage scavenger receptor 1 decreases expression ISO Sirolimus results in decreased expression of MSR1 mRNA CTD PMID:17016853 NCBI chr 8:39,996,284...40,095,790
Ensembl chr 8:40,034,726...40,095,714 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions
decreases activity
decreases expression
increases activity
decreases phosphorylation
increases phosphorylation
increases expression
affects binding		 ISO
EXP		 [Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein; [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein; [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to Fulvestrant; [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species; Curcumin promotes the reaction [Sirolimus results in decreased phosphorylation of MTOR protein]; MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sevoflurane promotes the reaction [Sirolimus results in decreased phosphorylation of MTOR protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA]; Sirolimus inhibits the reaction [Palmitic Acid results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in decreased expression of and results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [hydroquinone results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [Sevoflurane results in decreased phosphorylation of MTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]; Sirolimus results in decreased expression of and results in decreased phosphorylation of MTOR protein; Sirolimus results in decreased phosphorylation of and results in increased expression of MTOR protein; sodium arsenite promotes the reaction [Sirolimus results in decreased expression of MTOR protein]
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of MTOR protein
Sirolimus results in decreased expression of MTOR mRNA; Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form
Sirolimus results in increased activity of MTOR protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol affects the susceptibility to Lipopolysaccharides]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased susceptibility to Resveratrol; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Creatine results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [cypermethrin results in decreased phosphorylation of MTOR protein]
Sirolimus results in increased phosphorylation of MTOR protein
Sirolimus results in increased expression of MTOR mRNA
[Silicon Dioxide co-treated with Sirolimus] results in decreased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]
Sirolimus results in increased expression of MTOR protein modified form
Sirolimus binds to MTOR protein		 CTD PMID:11602639 PMID:12087098 PMID:14673156 PMID:15050414 PMID:15782132 More... NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140 		JBrowse link
G Mturn maturin, neural progenitor differentiation regulator homolog (Xenopus) multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] CTD PMID:21245298 NCBI chr 6:54,658,609...54,680,840
Ensembl chr 6:54,658,609...54,680,836 		JBrowse link
G Mybl2 myeloblastosis oncogene-like 2 multiple interactions EXP [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein CTD PMID:12417722 NCBI chr 2:162,896,246...162,926,608
Ensembl chr 2:162,896,607...162,926,608 		JBrowse link
G Myc myelocytomatosis oncogene multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of MYC protein; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of MYC mRNA; [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein CTD PMID:20054642 PMID:25307878 NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223 		JBrowse link
G Myf5 myogenic factor 5 decreases expression EXP Sirolimus results in decreased expression of MYF5 protein CTD PMID:30905858 NCBI chr10:107,318,769...107,322,787
Ensembl chr10:107,318,769...107,321,995 		JBrowse link
G Myh11 myosin, heavy polypeptide 11, smooth muscle multiple interactions
increases expression		 ISO [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein
Sirolimus results in increased expression of MYH11 protein		 CTD PMID:17908691 NCBI chr16:14,012,392...14,109,227
Ensembl chr16:14,012,399...14,109,236 		JBrowse link
G Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]] CTD PMID:25045214 NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083 		JBrowse link
G Mylk myosin, light polypeptide kinase multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] CTD PMID:21245298 NCBI chr16:34,565,569...34,822,806
Ensembl chr16:34,565,580...34,822,790 		JBrowse link
G Myod1 myogenic differentiation 1 affects expression EXP Sirolimus affects the expression of MYOD1 protein CTD PMID:30905858 NCBI chr 7:46,025,898...46,028,516
Ensembl chr 7:46,025,898...46,028,523 		JBrowse link
G Myof myoferlin multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] CTD PMID:21245298 NCBI chr19:37,887,484...38,032,025
Ensembl chr19:37,887,484...38,032,025 		JBrowse link
G Naip2 NLR family, apoptosis inhibitory protein 2 decreases expression EXP Sirolimus results in decreased expression of NAIP mRNA CTD PMID:9836529 NCBI chr13:100,280,571...100,338,630
Ensembl chr13:100,280,571...100,338,600 		JBrowse link
G Nanog Nanog homeobox increases expression EXP Sirolimus results in increased expression of NANOG mRNA CTD PMID:21681844 NCBI chr 6:122,684,448...122,691,592
Ensembl chr 6:122,684,448...122,691,592 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions
decreases expression		 ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein]
Sirolimus results in decreased expression of NCF1 protein		 CTD PMID:21195169 NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479 		JBrowse link
G Ncf2 neutrophil cytosolic factor 2 decreases expression
multiple interactions		 ISO Sirolimus results in decreased expression of NCF2 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein]		 CTD PMID:21195169 NCBI chr 1:152,675,904...152,712,743
Ensembl chr 1:152,675,945...152,712,742 		JBrowse link
G Ncf4 neutrophil cytosolic factor 4 multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] CTD PMID:21195169 NCBI chr15:78,128,324...78,146,782
Ensembl chr15:78,129,001...78,146,780 		JBrowse link
G Ndc80 NDC80 kinetochore complex component multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA CTD PMID:19016759 NCBI chr17:71,803,095...71,833,852
Ensembl chr17:71,803,095...71,833,852 		JBrowse link
G Nek2 NIMA (never in mitosis gene a)-related expressed kinase 2 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA CTD PMID:19016759 NCBI chr 1:191,553,622...191,565,161
Ensembl chr 1:191,553,556...191,565,162 		JBrowse link
G Nfe2l2 nuclear factor, erythroid derived 2, like 2 multiple interactions
increases activity		 ISO
EXP		 NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein]
Sirolimus results in increased activity of NFE2L2 protein		 CTD PMID:28624451 PMID:30203046 NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985 		JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions ISO Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] CTD PMID:15571967 NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308 		JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
Sirolimus inhibits the reaction [Isoproterenol results in increased degradation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein]		 CTD PMID:15571967 PMID:18789402 PMID:22363816 PMID:23211629 PMID:25045214 NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions
decreases expression		 ISO
EXP		 Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]
Sirolimus results in decreased expression of NLRP3 protein
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of NLRP3 mRNA]		 CTD PMID:30205151 PMID:32645460 PMID:35405287 PMID:36849104 NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782 		JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA CTD PMID:19016759 NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347 		JBrowse link
G Nmu neuromedin U multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] CTD PMID:21245298 NCBI chr 5:76,481,342...76,511,624
Ensembl chr 5:76,481,342...76,511,635 		JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions EXP
ISO		 [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]		 CTD PMID:22363816 PMID:23211629 PMID:31499194 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080 		JBrowse link
G Nos3 nitric oxide synthase 3, endothelial cell multiple interactions
decreases expression
increases phosphorylation		 ISO
EXP		 Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]
Sirolimus results in decreased expression of NOS3 mRNA; Sirolimus results in decreased expression of NOS3 protein
Sirolimus results in increased phosphorylation of NOS3 protein		 CTD PMID:17261647 PMID:19520256 PMID:19815708 NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472 		JBrowse link
G Notch1 notch 1 affects expression ISO Sirolimus affects the expression of NOTCH1 protein CTD PMID:26676567 NCBI chr 2:26,347,914...26,393,834
Ensembl chr 2:26,347,915...26,406,675 		JBrowse link
G Nphs2 nephrosis 2, podocin affects expression ISO Sirolimus affects the expression of NPHS2 protein CTD PMID:19671594 NCBI chr 1:156,138,105...156,155,605
Ensembl chr 1:156,138,297...156,155,605 		JBrowse link
G Nppa natriuretic peptide type A multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]; Sirolimus inhibits the reaction [rosiglitazone results in increased expression of NPPA mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]] CTD PMID:19397913 PMID:25045214 NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536 		JBrowse link
G Nppb natriuretic peptide type B multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]] CTD PMID:25045214 NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 affects expression
increases expression		 ISO Sirolimus affects the expression of NR1H3 protein
Sirolimus increases expression of NR1H3 mRNA in macrophages		 CTD
RGD		 PMID:17016853 PMID:17016853 RGD:401827916 NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] CTD PMID:21245298 NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases activity EXP Sirolimus results in increased activity of NR3C1 protein CTD PMID:15697228 NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474 		JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO Sirolimus inhibits the reaction [Ethanol results in decreased expression of NR5A1 protein] CTD PMID:29524503 NCBI chr 2:38,582,668...38,604,554
Ensembl chr 2:38,582,668...38,604,554 		JBrowse link
G Nxt1 NTF2-related export protein 1 decreases expression EXP Sirolimus results in decreased expression of NXT1 mRNA CTD PMID:11355896 NCBI chr 2:148,514,535...148,517,946
Ensembl chr 2:148,514,521...148,517,947 		JBrowse link
G Ogn osteoglycin increases expression ISO Sirolimus results in increased expression of OGN mRNA CTD PMID:21865292 NCBI chr13:49,761,491...49,777,977
Ensembl chr13:49,761,522...49,777,977 		JBrowse link
G Olr1 oxidized low density lipoprotein (lectin-like) receptor 1 affects expression ISO Sirolimus affects the expression of OLR1 protein CTD PMID:17016853 NCBI chr 6:129,456,113...129,484,312
Ensembl chr 6:129,462,207...129,484,128 		JBrowse link
G Optn optineurin multiple interactions EXP Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] CTD PMID:25884947 NCBI chr 2:5,023,902...5,069,210
Ensembl chr 2:5,025,453...5,068,862 		JBrowse link
G Otud7b OTU domain containing 7B multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]]
Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]]		 CTD PMID:36639017 NCBI chr 3:96,011,759...96,068,446
Ensembl chr 3:96,011,839...96,068,446 		JBrowse link
G Oxa1l oxidase assembly 1-like multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] CTD PMID:21245298 NCBI chr14:54,598,298...54,607,130
Ensembl chr14:54,598,291...54,607,130 		JBrowse link
G Pabpc1 poly(A) binding protein, cytoplasmic 1 multiple interactions
decreases expression		 ISO Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]
Sirolimus results in decreased expression of PABPC1 protein		 CTD PMID:25940091 NCBI chr15:36,595,902...36,609,825
Ensembl chr15:36,595,905...36,609,912 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions
increases cleavage
increases expression		 ISO
EXP		 [Sirolimus co-treated with ovatodiolide] results in increased cleavage of PARP1 protein; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [ovatodiolide results in increased cleavage of PARP1 protein]
Sirolimus results in increased cleavage of PARP1 protein
Sirolimus results in increased expression of PARP1 protein modified form
[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein; Sirolimus inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein]
Sirolimus promotes the reaction [Cadmium results in increased cleavage of PARP1 protein]		 CTD PMID:19682553 PMID:21410490 PMID:24304514 PMID:25307878 PMID:26825372 More... NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819 		JBrowse link
G Pax8 paired box 8 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] CTD PMID:21245298 NCBI chr 2:24,310,563...24,365,611
Ensembl chr 2:24,310,572...24,365,611 		JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1, cytosolic multiple interactions ISO [troglitazone co-treated with Sirolimus] results in decreased expression of PCK1 mRNA CTD PMID:10446394 NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
decreases expression		 ISO
EXP		 [fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA
Sirolimus results in decreased expression of PCNA protein
Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]		 CTD PMID:9151781 PMID:11355896 PMID:19016759 NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234 		JBrowse link
G Pdcd4 programmed cell death 4 multiple interactions
increases expression
increases stability		 ISO
EXP		 [resveratrol co-treated with Sirolimus] results in increased stability of PDCD4 protein; Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein]
Sirolimus results in increased expression of PDCD4 mRNA; Sirolimus results in increased expression of PDCD4 protein
Sirolimus results in increased stability of PDCD4 protein
[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein; PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 mRNA]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein]
resveratrol inhibits the reaction [Sirolimus results in increased stability of PDCD4 protein]		 CTD PMID:17259349 PMID:24304514 PMID:24356939 PMID:26369790 NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291 		JBrowse link
G Pdgfb platelet derived growth factor, B polypeptide multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] CTD PMID:15919668 NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha decreases response to substance
multiple interactions
increases activity
increases expression		 ISO
EXP		 Sirolimus results in decreased susceptibility to PIK3CA protein
Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA]; Wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein]
Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]
Sirolimus results in increased expression of PIK3CA mRNA		 CTD PMID:10373522 PMID:16227402 PMID:27542212 PMID:31522336 NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635 		JBrowse link
G Pik3cb phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta multiple interactions
increases expression		 EXP Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]
Sirolimus results in increased expression of PIK3CB mRNA		 CTD PMID:31522336 NCBI chr 9:98,920,455...99,022,264
Ensembl chr 9:98,918,707...99,022,674 		JBrowse link
G Pik3cd phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta multiple interactions
increases expression		 EXP Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]
Sirolimus results in increased expression of PIK3CD mRNA		 CTD PMID:31522336 NCBI chr 4:149,733,625...149,787,023
Ensembl chr 4:149,733,625...149,787,028 		JBrowse link
G Pik3cg phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma decreases expression
multiple interactions		 EXP Sirolimus results in decreased expression of PIK3CG mRNA
Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CG mRNA]		 CTD PMID:31522336 NCBI chr12:32,223,128...32,258,675
Ensembl chr12:32,223,472...32,258,658 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] CTD PMID:17908691 NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725 		JBrowse link
G Pim1 proviral integration site 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of PIM1 mRNA CTD PMID:25307878 NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086 		JBrowse link
G Pink1 PTEN induced putative kinase 1 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PINK1 protein]
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PINK1 protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of PINK1 protein]		 CTD PMID:33823232 PMID:35405287 NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618 		JBrowse link
G Pkm pyruvate kinase, muscle multiple interactions
increases expression		 ISO [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of PKM protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of PKM protein] CTD PMID:22574221 PMID:36336208 PMID:36640941 NCBI chr 9:59,563,859...59,586,655
Ensembl chr 9:59,563,651...59,586,658 		JBrowse link
G Pkp4 plakophilin 4 increases expression ISO Sirolimus results in increased expression of PKP4 mRNA CTD PMID:21865292 NCBI chr 2:58,991,123...59,185,549
Ensembl chr 2:58,991,194...59,185,552 		JBrowse link
G Plcl1 phospholipase C-like 1 increases expression ISO Sirolimus results in increased expression of PLCL1 mRNA CTD PMID:24356939 NCBI chr 1:55,442,722...55,793,444
Ensembl chr 1:55,445,080...55,793,444 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein CTD PMID:20686837 NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636 		JBrowse link
G Pml promyelocytic leukemia increases expression
decreases response to substance
increases localization		 ISO Sirolimus results in increased expression of PML protein
PML protein results in decreased susceptibility to Sirolimus
Sirolimus results in increased localization of PML protein		 CTD PMID:23440206 NCBI chr 9:58,125,359...58,157,077
Ensembl chr 9:58,125,359...58,157,069 		JBrowse link
G Pmp22 peripheral myelin protein 22 increases metabolic processing EXP Sirolimus results in increased metabolism of PMP22 protein mutant form CTD PMID:20739560 NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373 		JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 increases expression EXP Sirolimus results in increased expression of PNPLA2 mRNA; Sirolimus results in increased expression of PNPLA2 protein CTD PMID:20068142 NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656 		JBrowse link
G Pnrc1 proline-rich nuclear receptor coactivator 1 increases expression ISO Sirolimus results in increased expression of PNRC1 mRNA CTD PMID:24356939 NCBI chr 4:33,245,423...33,248,787
Ensembl chr 4:33,245,423...33,290,163 		JBrowse link
G Pold2 polymerase (DNA directed), delta 2, regulatory subunit decreases expression EXP Sirolimus results in decreased expression of POLD2 mRNA CTD PMID:11355896 NCBI chr11:5,822,180...5,828,256
Ensembl chr11:5,822,180...5,828,292 		JBrowse link
G Polr1h RNA polymerase I subunit H multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA] CTD PMID:21245298 NCBI chr17:37,265,250...37,269,417
Ensembl chr17:37,265,248...37,269,451 		JBrowse link
G Postn periostin, osteoblast specific factor multiple interactions ISO Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458 		JBrowse link
G Pou5f1 POU domain, class 5, transcription factor 1 increases expression EXP Sirolimus results in increased expression of POU5F1 mRNA; Sirolimus results in increased expression of POU5F1 protein CTD PMID:21681844 NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]] CTD PMID:25045214 NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020 		JBrowse link
G Ppard peroxisome proliferator activator receptor delta multiple interactions EXP PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] CTD PMID:24898257 NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448 		JBrowse link
G Pparg peroxisome proliferator activated receptor gamma affects expression
multiple interactions
decreases expression		 ISO
EXP		 Sirolimus affects the expression of PPARG protein
[Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein
Sirolimus results in decreased expression of PPARG mRNA
Sirolimus inhibits the reaction [Endrin results in increased expression of PPARG mRNA]		 CTD PMID:15358118 PMID:17016853 PMID:34801515 NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360 		JBrowse link
G Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of PPARGC1A mRNA]		 CTD PMID:25045214 PMID:31499194 NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068 		JBrowse link
G Ppl periplakin increases expression ISO Sirolimus results in increased expression of PPL mRNA CTD PMID:21865292 NCBI chr16:4,904,155...4,950,345
Ensembl chr16:4,904,155...4,950,285 		JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory inhibitor subunit 1B multiple interactions EXP Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] CTD PMID:17209049 NCBI chr11:98,239,232...98,248,622
Ensembl chr11:98,239,230...98,248,622 		JBrowse link
G Ppp2r1b protein phosphatase 2, regulatory subunit A, beta multiple interactions ISO Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] CTD PMID:27542212 NCBI chr 9:50,767,946...50,810,625
Ensembl chr 9:50,756,601...50,805,529 		JBrowse link
G Prcp prolylcarboxypeptidase (angiotensinase C) increases expression ISO Sirolimus results in increased expression of PRCP mRNA CTD PMID:21865292 NCBI chr 7:92,524,461...92,583,789
Ensembl chr 7:92,523,678...92,583,791 		JBrowse link
G Prf1 perforin 1 (pore forming protein) decreases expression ISO Sirolimus results in decreased expression of PRF1 protein CTD PMID:16477233 NCBI chr10:61,133,530...61,140,463
Ensembl chr10:61,133,612...61,140,459 		JBrowse link
G Prkaa1 protein kinase, AMP-activated, alpha 1 catalytic subunit multiple interactions ISO Sirolimus inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein] CTD PMID:21195169 NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380 		JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of PRKCA protein] CTD PMID:23000059 NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754 		JBrowse link
G Prkcd protein kinase C, delta affects localization
decreases phosphorylation
multiple interactions		 ISO Sirolimus affects the localization of PRKCD protein
Sirolimus results in decreased phosphorylation of PRKCD protein
sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein]		 CTD PMID:20082316 NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167 		JBrowse link
G Prkcg protein kinase C, gamma increases degradation
multiple interactions		 ISO Sirolimus results in increased degradation of PRKCG protein mutant form
Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form]		 CTD PMID:20398063 NCBI chr 7:3,352,038...3,379,615
Ensembl chr 7:3,337,704...3,379,615 		JBrowse link
G Prkch protein kinase C, eta decreases response to substance
multiple interactions		 ISO PRKCH results in decreased susceptibility to Sirolimus
[Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]		 CTD PMID:16832347 NCBI chr12:73,631,570...73,824,959
Ensembl chr12:73,631,570...73,824,959 		JBrowse link
G Prkd2 protein kinase D2 multiple interactions ISO PRKD2 protein affects the reaction [Sirolimus results in increased lipidation of MAP1LC3B protein] CTD PMID:37951334 NCBI chr 7:16,576,827...16,604,386
Ensembl chr 7:16,576,827...16,604,389 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PRKN protein]
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PRKN protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of PRKN protein]		 CTD PMID:33823232 PMID:35405287 NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248 		JBrowse link
G Prlr prolactin receptor decreases expression ISO Sirolimus results in decreased expression of PRLR mRNA CTD PMID:21865292 NCBI chr15:10,177,324...10,349,276
Ensembl chr15:10,177,324...10,349,266 		JBrowse link
G Prmt5 protein arginine N-methyltransferase 5 increases activity ISO Sirolimus results in increased activity of PRMT5 protein CTD PMID:31473880 NCBI chr14:54,744,639...54,754,927
Ensembl chr14:54,744,644...54,754,982 		JBrowse link
G Psma1 proteasome subunit alpha 1 decreases expression EXP Sirolimus results in decreased expression of PSMA1 mRNA CTD PMID:11355896 NCBI chr 7:113,863,785...113,875,351
Ensembl chr 7:113,863,841...113,875,353 		JBrowse link
G Psma4 proteasome subunit alpha 4 decreases expression EXP Sirolimus results in decreased expression of PSMA4 mRNA CTD PMID:11355896 NCBI chr 9:54,858,074...54,865,316
Ensembl chr 9:54,858,074...54,865,314 		JBrowse link
G Psmd11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 decreases expression ISO Sirolimus results in decreased expression of PSMD11 mRNA; Sirolimus results in decreased expression of PSMD11 protein CTD PMID:15782132 NCBI chr11:80,319,441...80,364,074
Ensembl chr11:80,319,441...80,364,074 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
decreases response to substance
decreases expression		 ISO
EXP		 [Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]
PTEN protein results in decreased susceptibility to Sirolimus
Sirolimus results in decreased expression of PTEN protein
Sirolimus inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein]		 CTD PMID:18303120 PMID:18622747 PMID:19625624 PMID:21195169 PMID:31676321 NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560 		JBrowse link
G Ptger1 prostaglandin E receptor 1 (subtype EP1) multiple interactions ISO Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] CTD PMID:20335389 NCBI chr 8:84,393,171...84,399,385
Ensembl chr 8:84,393,307...84,399,382 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
affects expression		 EXP
ISO		 [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of PTGS2 protein]
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein]
Sirolimus affects the expression of PTGS2 mRNA		 CTD PMID:22363816 PMID:23211629 PMID:24971338 PMID:36115647 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978 		JBrowse link
G Ptk2 PTK2 protein tyrosine kinase 2 decreases phosphorylation EXP Sirolimus results in decreased phosphorylation of PTK2 protein CTD PMID:19922502 NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129 		JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 multiple interactions ISO Sirolimus inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] CTD PMID:17623046 NCBI chr 7:46,727,543...46,783,774
Ensembl chr 7:46,727,543...46,783,432 		JBrowse link
G Ptprc protein tyrosine phosphatase receptor type C increases expression EXP Sirolimus results in increased expression of PTPRC mRNA CTD PMID:11355896 NCBI chr 1:137,990,601...138,103,491
Ensembl chr 1:137,990,599...138,103,446 		JBrowse link
G Pttg1 pituitary tumor-transforming gene 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA CTD PMID:19016759 NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078 		JBrowse link
G Pycard PYD and CARD domain containing multiple interactions EXP Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of PYCARD mRNA] CTD PMID:36849104 NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039 		JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression
multiple interactions		 ISO Sirolimus results in decreased expression of RAC1 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein]		 CTD PMID:21195169 NCBI chr 5:143,491,236...143,513,786
Ensembl chr 5:143,489,389...143,513,791 		JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA CTD PMID:19016759 NCBI chr 2:118,943,295...118,966,554
Ensembl chr 2:118,943,274...118,977,926 		JBrowse link
G Raf1 v-raf-leukemia viral oncogene 1 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein CTD PMID:15767555 NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation		 ISO
EXP		 [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with letrozole] results in decreased expression of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]
[Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein]
Sirolimus results in decreased phosphorylation of RB1 protein		 CTD PMID:7532117 PMID:8419408 PMID:10373522 PMID:10849422 PMID:12393642 More... NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262 		JBrowse link
G Rbl1 RB transcriptional corepressor like 1 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr 2:156,987,813...157,046,454
Ensembl chr 2:156,987,813...157,046,454 		JBrowse link
G Rbl2 RB transcriptional corepressor like 2 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] CTD PMID:10373522 PMID:12417722 NCBI chr 8:91,796,685...91,850,472
Ensembl chr 8:91,796,685...91,850,472 		JBrowse link
G Rcan1 regulator of calcineurin 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of RCAN1 mRNA CTD PMID:25307878 NCBI chr16:92,188,839...92,263,057
Ensembl chr16:92,188,841...92,267,755 		JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of RELA protein]; Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
Sirolimus inhibits the reaction [Isoproterenol affects the localization of RELA protein]; Sirolimus inhibits the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein]		 CTD PMID:15571967 PMID:18789402 PMID:22003094 PMID:22363816 PMID:25045214 More... NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158 		JBrowse link
G Ren1 renin 1 structural increases expression ISO Sirolimus results in increased expression of REN mRNA CTD PMID:21865292 NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063 		JBrowse link
G Rest RE1-silencing transcription factor multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] CTD PMID:21245298 NCBI chr 5:77,413,273...77,434,279
Ensembl chr 5:77,413,338...77,434,279 		JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 decreases expression ISO Sirolimus results in decreased expression of RICTOR protein CTD PMID:18776922 NCBI chr15:6,737,827...6,829,882
Ensembl chr15:6,737,860...6,829,882 		JBrowse link
G Rpl32 ribosomal protein L32 multiple interactions
decreases expression		 ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA] CTD PMID:25940091 NCBI chr 6:115,782,475...115,785,704
Ensembl chr 6:115,782,466...115,785,708 		JBrowse link
G Rps20 ribosomal protein S20 multiple interactions
decreases expression		 ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA] CTD PMID:25940091 NCBI chr 4:3,831,334...3,835,600
Ensembl chr 4:3,831,334...3,835,665 		JBrowse link
G Rps27l ribosomal protein S27-like multiple interactions ISO Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] CTD PMID:21245298 NCBI chr 9:66,851,906...66,856,804
Ensembl chr 9:66,853,368...66,856,798 		JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases expression
increases phosphorylation
decreases phosphorylation		 ISO
EXP		 [Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
Sirolimus results in increased phosphorylation of RPS6 protein
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein		 CTD PMID:1614535 PMID:10373522 PMID:12939469 PMID:14502240 PMID:15297429 More... NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649 		JBrowse link
G Rps6ka1 ribosomal protein S6 kinase polypeptide 1 increases phosphorylation
affects localization
multiple interactions		 ISO
EXP		 Sirolimus results in increased phosphorylation of RPS6KA1 protein
Sirolimus affects the localization of RPS6KA1 protein
Sirolimus results in increased phosphorylation of and results in increased activity of RPS6KA1 protein		 CTD PMID:19151764 NCBI chr 4:133,574,601...133,615,466
Ensembl chr 4:133,574,601...133,615,108 		JBrowse link
G Rps6ka2 ribosomal protein S6 kinase, polypeptide 2 affects localization
increases phosphorylation		 EXP Sirolimus affects the localization of RPS6KA2 protein
Sirolimus results in increased phosphorylation of RPS6KA2 protein		 CTD PMID:19151764 NCBI chr17:7,356,384...7,570,714
Ensembl chr17:7,437,514...7,570,714 		JBrowse link
G Rps6ka3 ribosomal protein S6 kinase polypeptide 3 affects localization
increases phosphorylation		 EXP Sirolimus affects the localization of RPS6KA3 protein
Sirolimus results in increased phosphorylation of RPS6KA3 protein		 CTD PMID:19151764 NCBI chr  X:158,038,652...158,151,240
Ensembl chr  X:157,993,303...158,151,240 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 multiple interactions
decreases activity
decreases phosphorylation
decreases expression
increases phosphorylation
increases expression		 ISO
EXP		 [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with Oxygen deficiency] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein]
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of RPS6KB1 protein
[[manganese chloride results in increased abundance of Manganese] which co-treated with Sirolimus] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein; MRK 003 promotes the reaction [Sirolimus results in decreased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Propranolol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus promotes the reaction [MRK 003 results in decreased activity of RPS6KB1 protein]; Sirolimus promotes the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]
[Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein
Sirolimus results in decreased phosphorylation of RPS6KB1 protein; Sirolimus results in decreased phosphorylation of S6K protein
Sirolimus results in decreased expression of RPS6KB1 protein modified form
Sirolimus results in increased phosphorylation of RPS6KB1 protein
Sirolimus results in increased expression of RPS6KB1 protein modified form		 CTD PMID:12411397 PMID:14516795 PMID:14673156 PMID:15070696 PMID:15297429 More... NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631 		JBrowse link
G Rps6kb2 ribosomal protein S6 kinase, polypeptide 2 multiple interactions
decreases activity		 ISO MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] CTD PMID:12087098 NCBI chr19:4,206,791...4,213,382
Ensembl chr19:4,203,990...4,213,353 		JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 multiple interactions ISO [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in decreased phosphorylation of RPTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] CTD PMID:18776922 PMID:19505958 PMID:21742779 PMID:22863860 PMID:25940091 NCBI chr11:119,493,731...119,790,417
Ensembl chr11:119,493,731...119,790,402 		JBrowse link
G Rrad Ras-related associated with diabetes multiple interactions ISO Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] CTD PMID:21245298 NCBI chr 8:105,354,702...105,357,921
Ensembl chr 8:105,354,702...105,357,959 		JBrowse link
G Rtn4 reticulon 4 multiple interactions ISO Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4 protein] CTD PMID:26648565 NCBI chr11:29,642,898...29,694,414
Ensembl chr11:29,642,947...29,694,331 		JBrowse link
G Rtn4r reticulon 4 receptor multiple interactions ISO Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4R protein] CTD PMID:26648565 NCBI chr16:17,945,506...17,970,272
Ensembl chr16:17,945,506...17,970,272 		JBrowse link
G Runx2 runt related transcription factor 2 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]
Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]]		 CTD PMID:23111315 PMID:33450223 NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684 		JBrowse link
G S100a4 S100 calcium binding protein A4 decreases expression ISO Sirolimus results in decreased expression of S100A4 mRNA CTD PMID:21865292 NCBI chr 3:90,511,077...90,513,349
Ensembl chr 3:90,511,078...90,513,352 		JBrowse link
G S100g S100 calcium binding protein G increases expression ISO Sirolimus results in increased expression of S100G mRNA CTD PMID:21865292 NCBI chr  X:161,744,988...161,747,595
Ensembl chr  X:161,744,988...161,747,595 		JBrowse link
G S1pr1 sphingosine-1-phosphate receptor 1 increases expression ISO Sirolimus results in increased expression of S1PR1 mRNA CTD PMID:24356939 NCBI chr 3:115,504,082...115,508,704
Ensembl chr 3:115,504,082...115,508,721 		JBrowse link
G Scarb2 scavenger receptor class B, member 2 decreases expression ISO Sirolimus results in decreased expression of SCARB2 mRNA CTD PMID:17016853 NCBI chr 5:92,589,170...92,653,516
Ensembl chr 5:92,589,173...92,654,692 		JBrowse link
G Scd2 stearoyl-Coenzyme A desaturase 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] CTD PMID:21245298 NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303 		JBrowse link
G Sema3a sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A multiple interactions ISO Sirolimus inhibits the reaction [chromium hexavalent ion results in increased expression of SEMA3A protein] CTD PMID:30236763 NCBI chr 5:13,174,789...13,653,453
Ensembl chr 5:13,175,381...13,652,533 		JBrowse link
G Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] CTD PMID:21245298 NCBI chr 5:17,779,814...17,935,266
Ensembl chr 5:17,779,279...17,935,266 		JBrowse link
G Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N increases expression ISO Sirolimus results in increased expression of SERPINA3N mRNA CTD PMID:21865292 NCBI chr12:104,372,967...104,380,588
Ensembl chr12:104,372,988...104,380,588 		JBrowse link
G Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]]		 CTD PMID:21245298 PMID:31499194 NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122 		JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SESN2 mRNA CTD PMID:25307878 NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812 		JBrowse link
G Shank3 SH3 and multiple ankyrin repeat domains 3 multiple interactions EXP Sirolimus inhibits the reaction [phenanthrene results in decreased expression of SHANK3 mRNA] CTD PMID:34453960 NCBI chr15:89,376,929...89,444,464
Ensembl chr15:89,383,826...89,444,464 		JBrowse link
G Shisa2 shisa family member 2 increases expression ISO Sirolimus results in increased expression of SHISA2 mRNA CTD PMID:24356939 NCBI chr14:59,862,730...59,869,109
Ensembl chr14:59,862,757...59,869,109 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
increases expression
increases response to substance		 ISO [(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of SIRT1 protein; Aspirin inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]
Sirolimus inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Sirolimus results in increased expression of SIRT1 protein
SIRT1 protein results in increased susceptibility to Sirolimus		 CTD PMID:19520256 PMID:22561310 PMID:25307878 NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483 		JBrowse link
G Sirt2 sirtuin 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] CTD PMID:21245298 NCBI chr 7:28,466,192...28,488,086
Ensembl chr 7:28,466,160...28,488,086 		JBrowse link
G Sirt4 sirtuin 4 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]
Sirolimus affects the reaction [SIRT4 protein affects the reaction [Doxorubicin affects the expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]		 CTD PMID:35134463 NCBI chr 5:115,616,065...115,628,322
Ensembl chr 5:115,616,069...115,622,784 		JBrowse link
G Skp2 S-phase kinase-associated protein 2 decreases expression ISO Sirolimus results in decreased expression of SKP2 protein CTD PMID:21092744 NCBI chr15:9,112,070...9,155,512
Ensembl chr15:9,112,073...9,155,512 		JBrowse link
G Slc12a1 solute carrier family 12, member 1 multiple interactions
decreases expression		 ISO rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of SLC12A1 protein] CTD PMID:19656910 NCBI chr 2:124,994,430...125,071,922
Ensembl chr 2:124,994,425...125,071,922 		JBrowse link
G Slc12a3 solute carrier family 12, member 3 increases expression ISO Sirolimus results in increased expression of SLC12A3 mRNA CTD PMID:21865292 NCBI chr 8:95,055,737...95,092,850
Ensembl chr 8:95,055,829...95,092,842 		JBrowse link
G Slc15a1 solute carrier family 15 (oligopeptide transporter), member 1 multiple interactions ISO Sirolimus inhibits the reaction [rosiglitazone results in increased expression of and results in increased activity of SLC15A1 protein] CTD PMID:22108913 NCBI chr14:121,697,033...121,742,666
Ensembl chr14:121,697,033...121,742,664 		JBrowse link
G Slc16a1 solute carrier family 16 (monocarboxylic acid transporters), member 1 decreases expression ISO Sirolimus results in decreased expression of SLC16A1 mRNA CTD PMID:21865292 NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778 		JBrowse link
G Slc22a13 solute carrier family 22 (organic cation transporter), member 13 decreases expression ISO Sirolimus results in decreased expression of SLC22A13 mRNA CTD PMID:21865292 NCBI chr 9:119,020,618...119,038,171
Ensembl chr 9:119,022,040...119,038,164 		JBrowse link
G Slc2a1 solute carrier family 2 (facilitated glucose transporter), member 1 multiple interactions ISO Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC2A1 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of SLC2A1 protein] CTD PMID:36336208 NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180 		JBrowse link
G Slc31a1 solute carrier family 31, member 1 multiple interactions ISO Sirolimus affects the reaction [SLC31A1 protein affects the expression of BAX protein]; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BCL2 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of AKT1 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of MTOR protein] CTD PMID:37290678 NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006 		JBrowse link
G Slc5a1 solute carrier family 5 (sodium/glucose cotransporter), member 1 decreases expression ISO Sirolimus results in decreased expression of SLC5A1 mRNA CTD PMID:21865292 NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214 		JBrowse link
G Slc7a12 solute carrier family 7 (cationic amino acid transporter, y+ system), member 12 increases expression ISO Sirolimus results in increased expression of SLC7A12 mRNA CTD PMID:21865292 NCBI chr 3:14,545,757...14,570,879
Ensembl chr 3:14,545,757...14,570,890 		JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression ISO Sirolimus results in increased expression of SLCO1A4 mRNA CTD PMID:11589784 NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925 		JBrowse link
G Smim14 small integral membrane protein 14 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] CTD PMID:21245298 NCBI chr 5:65,604,187...65,694,492
Ensembl chr 5:65,604,187...65,694,527 		JBrowse link
G Snai1 snail family zinc finger 1 increases expression
multiple interactions		 ISO Sirolimus results in increased expression of SNAI1 protein
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of SNAI1 mRNA]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of SNAI1 mRNA]		 CTD PMID:28624451 PMID:28888487 PMID:30053495 NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734 		JBrowse link
G Snca synuclein, alpha multiple interactions ISO Sirolimus inhibits the reaction [Paraquat results in increased expression of SNCA protein] CTD PMID:32306690 NCBI chr 6:60,708,557...60,806,839
Ensembl chr 6:60,708,559...60,806,839 		JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial decreases expression EXP Sirolimus results in decreased expression of SOD2 protein CTD PMID:30905858 NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950 		JBrowse link
G Sox2 SRY (sex determining region Y)-box 2 increases expression EXP Sirolimus results in increased expression of SOX2 mRNA CTD PMID:21681844 NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610 		JBrowse link
G Sox9 SRY (sex determining region Y)-box 9 decreases expression EXP Sirolimus results in decreased expression of SOX9 protein CTD PMID:34536393 NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] CTD PMID:31051157 NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
increases expression
increases degradation		 EXP
ISO		 [Sirolimus co-treated with Cadmium] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with gelsenicine] results in decreased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus affects the reaction [SIRT4 protein affects the reaction [Doxorubicin affects the expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in decreased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Ethanol results in decreased expression of SQSTM1 protein]
[Sirolimus co-treated with cadmium acetate] results in decreased expression of SQSTM1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [manganese chloride results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]]
[AICA ribonucleotide co-treated with Sirolimus] results in increased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; Curcumin inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [honokiol results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [lead acetate results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [ovatodiolide results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased degradation of SQSTM1 protein]
Sirolimus results in increased expression of SQSTM1 protein
Sirolimus results in increased degradation of SQSTM1 protein		 CTD PMID:19773376 PMID:24238063 PMID:24304514 PMID:25884947 PMID:28025121 More... NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654 		JBrowse link
G Src Rous sarcoma oncogene multiple interactions EXP [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in decreased phosphorylation of SRC protein]; Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein CTD PMID:19151764 PMID:31499194 NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression EXP Sirolimus results in decreased expression of SREBF1 mRNA CTD PMID:15358118 NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407 		JBrowse link
G Srr serine racemase multiple interactions ISO Sirolimus inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] CTD PMID:24012499 NCBI chr11:74,794,853...74,818,427
Ensembl chr11:74,797,185...74,816,774 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions EXP Sirolimus inhibits the reaction [Polystyrenes analog results in decreased expression of STAR protein] CTD PMID:36709824 NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010 		JBrowse link
G Stard10 StAR related lipid transfer domain containing 10 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] CTD PMID:21245298 NCBI chr 7:100,966,293...100,995,833
Ensembl chr 7:100,966,293...100,995,833 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions		 ISO Sirolimus results in decreased phosphorylation of STAT3 protein
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of STAT3 protein]		 CTD PMID:16391472 PMID:16427044 PMID:20038814 PMID:26648565 NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366 		JBrowse link
G Sts steroid sulfatase multiple interactions ISO Sirolimus inhibits the reaction [Tretinoin results in increased activity of STS protein] CTD PMID:16178010 NCBI chr  X:168,856,332...169,015,037
Ensembl chr  X:168,909,030...169,014,924 		JBrowse link
G Suv39h1 suppressor of variegation 3-9 1 multiple interactions ISO [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein CTD PMID:31676321 NCBI chr  X:7,927,401...7,940,994
Ensembl chr  X:7,927,410...7,940,999 		JBrowse link
G Syn1 synapsin I multiple interactions EXP Sirolimus inhibits the reaction [Ketamine results in increased expression of SYN1 protein] CTD PMID:33022268 NCBI chr  X:20,726,750...20,787,157
Ensembl chr  X:20,726,750...20,787,243 		JBrowse link
G Syt1 synaptotagmin I multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] CTD PMID:21245298 NCBI chr10:108,333,511...108,846,852
Ensembl chr10:108,333,511...108,846,843 		JBrowse link
G Taf12 TATA-box binding protein associated factor 12 decreases expression EXP Sirolimus results in decreased expression of TAF12 mRNA CTD PMID:11355896 NCBI chr 4:132,001,667...132,020,640
Ensembl chr 4:132,001,686...132,023,077 		JBrowse link
G Tal1 T cell acute lymphocytic leukemia 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] CTD PMID:21245298 NCBI chr 4:114,913,623...114,928,952
Ensembl chr 4:114,913,623...114,928,952 		JBrowse link
G Tardbp TAR DNA binding protein multiple interactions EXP Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and affects the localization of TARDBP protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein] CTD PMID:25884947 PMID:35405287 NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476 		JBrowse link
G Tars1 threonyl-tRNA synthetase 1 decreases expression EXP Sirolimus results in decreased expression of TARS1 mRNA CTD PMID:11355896 NCBI chr15:11,383,749...11,399,744
Ensembl chr15:11,382,387...11,399,751 		JBrowse link
G Tax1bp1 Tax1 (human T cell leukemia virus type I) binding protein 1 increases expression EXP Sirolimus results in increased expression of TAX1BP1 mRNA CTD PMID:11355896 NCBI chr 6:52,690,677...52,743,765
Ensembl chr 6:52,690,714...52,743,765 		JBrowse link
G Tcf19 transcription factor 19 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TCF19 mRNA CTD PMID:19016759 NCBI chr17:35,823,627...35,827,730
Ensembl chr17:35,823,631...35,827,721 		JBrowse link
G Tead1 TEA domain family member 1 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] CTD PMID:21245298 NCBI chr 7:112,278,563...112,505,991
Ensembl chr 7:112,278,525...112,506,014 		JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO Sirolimus results in decreased expression of TERT mRNA; Sirolimus results in decreased expression of TERT protein CTD PMID:12939469 PMID:16455087 PMID:17996122 PMID:20863555 NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962 		JBrowse link
G Tfeb transcription factor EB affects localization
increases expression		 ISO Sirolimus affects the localization of TFEB protein
Sirolimus results in increased expression of TFEB protein		 CTD PMID:28366621 PMID:37951334 NCBI chr17:48,047,962...48,103,341
Ensembl chr17:48,047,955...48,103,344 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases response to substance
decreases expression		 ISO
EXP		 [Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]; Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CG mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]
TGFB1 protein results in increased susceptibility to Sirolimus
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
Sirolimus results in decreased expression of TGFB1 mRNA		 CTD PMID:10535884 PMID:12417722 PMID:14979923 PMID:17050028 PMID:17550925 More... NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502 		JBrowse link
G Tgfbr3 transforming growth factor, beta receptor III increases expression EXP Sirolimus results in increased expression of TGFBR3 mRNA CTD PMID:11355896 NCBI chr 5:107,254,433...107,437,495
Ensembl chr 5:107,254,436...107,437,495 		JBrowse link
G Tgm2 transglutaminase 2, C polypeptide decreases expression EXP Sirolimus results in decreased expression of TGM2 mRNA CTD PMID:11355896 NCBI chr 2:157,958,325...157,988,312
Ensembl chr 2:157,958,322...157,988,356 		JBrowse link
G Timeless timeless circadian clock 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TIMELESS mRNA CTD PMID:19016759 NCBI chr10:128,067,932...128,088,810
Ensembl chr10:128,067,934...128,088,810 		JBrowse link
G Timp3 tissue inhibitor of metalloproteinase 3 decreases expression ISO Sirolimus results in decreased expression of TIMP3 mRNA; Sirolimus results in decreased expression of TIMP3 protein CTD PMID:21742783 NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370 		JBrowse link
G Tmem14c transmembrane protein 14C multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] CTD PMID:21245298 NCBI chr13:41,169,726...41,176,058
Ensembl chr13:41,169,768...41,176,062 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
decreases secretion
decreases expression		 ISO
EXP		 [Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein; Sirolimus inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus results in increased expression of TNF
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]
Sirolimus results in decreased secretion of TNF protein
Sirolimus results in decreased expression of TNF mRNA
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Silicon Dioxide results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]		 CTD PMID:12531798 PMID:14502240 PMID:16314788 PMID:19567381 PMID:19810018 More... NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983 		JBrowse link
G Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 multiple interactions EXP Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483 		JBrowse link
G Tpp2 tripeptidyl peptidase II multiple interactions EXP Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein] CTD PMID:20643100 NCBI chr 1:43,973,130...44,042,160
Ensembl chr 1:43,972,807...44,042,160 		JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of TRIB3 mRNA CTD PMID:25307878 NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952 		JBrowse link
G Trp53 transformation related protein 53 multiple interactions
decreases phosphorylation
increases expression		 ISO
EXP		 [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein]
Sirolimus results in decreased phosphorylation of TP53 protein
Sirolimus results in increased expression of TP53 mRNA
Sirolimus inhibits the reaction [arsenite results in increased expression of and results in increased phosphorylation of TRP53 protein]		 CTD PMID:11602639 PMID:19560264 PMID:23396362 PMID:24971338 PMID:30555576 NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699 		JBrowse link
G Trp63 transformation related protein 63 decreases expression ISO
EXP		 Sirolimus results in decreased expression of TP63 protein
Sirolimus results in decreased expression of TRP63 protein		 CTD PMID:20038814 NCBI chr16:25,502,513...25,710,842
Ensembl chr16:25,502,513...25,710,852 		JBrowse link
G Trp73 transformation related protein 73 multiple interactions
increases expression		 ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein; Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ABTB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA]; Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter]; Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter]; Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA]; TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin]
Sirolimus results in increased expression of TP73 protein		 CTD PMID:20686837 PMID:21245298 NCBI chr 4:154,140,706...154,224,332
Ensembl chr 4:154,140,706...154,224,665 		JBrowse link
G Trpm6 transient receptor potential cation channel, subfamily M, member 6 multiple interactions
increases expression		 ISO rosiglitazone inhibits the reaction [Sirolimus results in increased expression of TRPM6 protein] CTD PMID:19656910 NCBI chr19:18,707,566...18,869,885
Ensembl chr19:18,727,347...18,869,875 		JBrowse link
G Tsc1 TSC complex subunit 1 multiple interactions EXP Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein] CTD PMID:18495876 NCBI chr 2:28,531,005...28,581,183
Ensembl chr 2:28,531,240...28,581,179 		JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with resveratrol] results in increased cleavage of PARP1 protein]
Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus co-treated with resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein]		 CTD PMID:19420259 PMID:24304514 PMID:31676321 NCBI chr17:24,814,788...24,851,607
Ensembl chr17:24,814,790...24,851,604 		JBrowse link
G Ttk Ttk protein kinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TTK mRNA CTD PMID:19016759 NCBI chr 9:83,716,704...83,754,442
Ensembl chr 9:83,716,742...83,754,442 		JBrowse link
G Tyms thymidylate synthase decreases expression ISO Sirolimus results in decreased expression of TYMS; Sirolimus results in decreased expression of TYMS mRNA CTD PMID:19764996 PMID:20682991 NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615 		JBrowse link
G Ulk1 unc-51 like kinase 1 multiple interactions
increases expression		 ISO Sirolimus affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein]
Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased expression of ULK1 protein]
Sirolimus results in increased expression of ULK1 protein		 CTD PMID:29128638 PMID:29518472 PMID:33070465 PMID:37329965 NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963 		JBrowse link
G Uri1 URI1, prefoldin-like chaperone decreases response to substance ISO URI1 results in decreased susceptibility to Sirolimus CTD PMID:21397856 NCBI chr 7:37,659,417...37,722,989
Ensembl chr 7:37,659,417...37,722,976 		JBrowse link
G Usp7 ubiquitin specific peptidase 7 multiple interactions ISO benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein]]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein] CTD PMID:32802178 NCBI chr16:8,506,586...8,574,931
Ensembl chr16:8,507,459...8,610,172 		JBrowse link
G Vasn vasorin decreases expression ISO Sirolimus results in decreased expression of VASN mRNA CTD PMID:17028423 NCBI chr16:4,457,809...4,469,030
Ensembl chr16:4,457,805...4,468,666 		JBrowse link
G Vcan versican increases expression ISO Sirolimus results in increased expression of VCAN mRNA CTD PMID:21865292 NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628 		JBrowse link
G Vcp valosin containing protein multiple interactions ISO
EXP		 Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]
Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein]		 CTD PMID:25884947 NCBI chr 4:42,979,964...43,000,507
Ensembl chr 4:42,979,963...43,000,507 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression		 ISO
EXP		 [Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
Sirolimus results in decreased expression of VEGFA mRNA
Sirolimus results in decreased expression of VEGFA protein
[Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of VEGFA mRNA
Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of VEGFA protein]		 CTD PMID:15050414 PMID:15930297 PMID:16682453 PMID:17968710 PMID:20554536 More... NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295 		JBrowse link
G Vim vimentin multiple interactions ISO Sirolimus inhibits the reaction [sodium arsenite results in increased expression of VIM protein]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]		 CTD PMID:28624451 PMID:28888487 NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637 		JBrowse link
G Wt1 WT1 transcription factor decreases expression ISO Sirolimus results in decreased expression of WT1 mRNA; Sirolimus results in decreased expression of WT1 protein; Sirolimus results in decreased expression of WT1 protein mutant form CTD PMID:15782132 PMID:18927120 NCBI chr 2:104,956,874...105,003,959
Ensembl chr 2:104,956,874...105,003,961 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Sirolimus inhibits the reaction [arsenite results in increased splicing of XBP1 mRNA] CTD PMID:22215663 NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO Sirolimus promotes the reaction [Cisplatin results in decreased expression of XIAP protein] CTD PMID:18058806 NCBI chr  X:41,148,483...41,198,541
Ensembl chr  X:41,148,556...41,198,533 		JBrowse link
G Ypel1 yippee like 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] CTD PMID:21245298 NCBI chr16:16,887,454...16,904,912
Ensembl chr16:16,887,560...16,904,909 		JBrowse link
G Yy1 YY1 transcription factor multiple interactions EXP Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of YY1 protein] CTD PMID:35445903 NCBI chr12:108,758,841...108,786,074
Ensembl chr12:108,758,899...108,786,074 		JBrowse link
G Zfp628 zinc finger protein 628 decreases expression ISO Sirolimus results in decreased expression of ZNF628 mRNA CTD PMID:24356939 NCBI chr 7:4,918,221...4,925,001
Ensembl chr 7:4,918,216...4,925,001 		JBrowse link
G Zic2 zinc finger protein of the cerebellum 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] CTD PMID:21245298 NCBI chr14:122,712,796...122,717,740
Ensembl chr14:122,712,847...122,717,264 		JBrowse link
G Zwint ZW10 interactor multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of ZWINT mRNA CTD PMID:19016759 NCBI chr10:72,490,678...72,510,796
Ensembl chr10:72,490,677...72,510,796 		JBrowse link
everolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP-binding cassette, sub-family B member 11 decreases activity ISO Everolimus results in decreased activity of ABCB11 protein CTD PMID:23956101 NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958 		JBrowse link
G Abcb1a ATP-binding cassette, sub-family B member 1A affects stability
affects response to substance
multiple interactions		 EXP
ISO		 ABCB1A protein affects the stability of Everolimus
ABCB1 polymorphism affects the susceptibility to Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan]		 CTD PMID:24727322 PMID:27169792 NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575 		JBrowse link
G Abcb1b ATP-binding cassette, sub-family B member 1B affects stability
multiple interactions		 EXP ABCB1B protein affects the stability of Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1B protein affects the metabolism of irinotecan]		 CTD PMID:24727322 NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 (Junior blood group) affects stability
multiple interactions		 EXP ABCG2 protein affects the stability of Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan]		 CTD PMID:24727322 NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661 		JBrowse link
G Akt1 thymoma viral proto-oncogene 1 increases phosphorylation
decreases phosphorylation		 ISO Everolimus results in increased phosphorylation of AKT1 protein
Everolimus results in decreased phosphorylation of AKT1 protein		 CTD PMID:16033851 PMID:22885370 PMID:23300809 PMID:28711525 NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions		 ISO Everolimus results in decreased expression of BIRC5 protein
Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]		 CTD PMID:21601561 PMID:28711525 PMID:28947240 NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569 		JBrowse link
G Brd4 bromodomain containing 4 multiple interactions ISO [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] CTD PMID:25537515 NCBI chr17:32,415,246...32,503,717
Ensembl chr17:32,415,248...32,503,696 		JBrowse link
G Casp3 caspase 3 increases cleavage ISO Everolimus results in increased cleavage of CASP3 protein CTD PMID:15940265 NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Everolimus results in decreased expression of CCNA2 protein CTD PMID:16856892 NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO Everolimus results in decreased expression of CCND1 protein
[letrozole co-treated with Everolimus] results in decreased expression of CCND1 protein		 CTD PMID:16033851 NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662 		JBrowse link
G Ccnd2 cyclin D2 multiple interactions
decreases expression		 ISO [letrozole co-treated with Everolimus] results in decreased expression of CCND2 protein
Everolimus results in decreased expression of CCND2 protein		 CTD PMID:16033851 NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO Everolimus results in decreased expression of CCND3 protein CTD PMID:16856892 NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616 		JBrowse link
G Cdh1 cadherin 1 increases expression ISO Everolimus results in increased expression of CDH1 protein CTD PMID:28258630 NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878 		JBrowse link
G Ces1d carboxylesterase 1D decreases activity ISO Everolimus results in decreased activity of CES1 protein CTD PMID:24727322 NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466 		JBrowse link
G Ces2h carboxylesterase 2H decreases activity ISO Everolimus results in decreased activity of CES2 protein CTD PMID:24727322 NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810 		JBrowse link
G Egfr epidermal growth factor receptor increases expression
multiple interactions		 ISO Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein
platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]		 CTD PMID:28711525 NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E increases phosphorylation
multiple interactions		 ISO Everolimus results in increased phosphorylation of EIF4E protein
Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein]		 CTD PMID:16033851 NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
decreases phosphorylation		 ISO [letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16033851 PMID:16856892 PMID:16951235 PMID:21372221 PMID:28711525 NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702 		JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4, gamma 1 multiple interactions ISO Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of EIF4G1 protein] CTD PMID:16033851 NCBI chr16:20,491,457...20,511,633
Ensembl chr16:20,487,063...20,511,634 		JBrowse link
G F3 coagulation factor III multiple interactions ISO Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697 		JBrowse link
G Igf1r insulin-like growth factor I receptor multiple interactions
increases expression		 ISO platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein]
Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein		 CTD PMID:28711525 NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416 		JBrowse link
G Itgam integrin alpha M multiple interactions ISO Everolimus promotes the reaction [Tretinoin results in increased expression of ITGAM protein] CTD PMID:29743969 NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Everolimus promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:32397857 NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Everolimus inhibits the reaction [4-cresol results in increased expression of MMP9 protein] CTD PMID:30910523 NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions
decreases activity		 ISO [Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin]
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]
Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein		 CTD PMID:16033851 PMID:20890178 PMID:21622721 PMID:24989011 PMID:30910523 NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140 		JBrowse link
G Myc myelocytomatosis oncogene multiple interactions
decreases response to substance
increases expression		 ISO [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene]
Everolimus results in increased expression of MYC protein		 CTD PMID:25537515 NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223 		JBrowse link
G Ngf nerve growth factor multiple interactions ISO Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] CTD PMID:24989011 NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329 		JBrowse link
G Nos3 nitric oxide synthase 3, endothelial cell multiple interactions
decreases expression		 ISO Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein] CTD PMID:19520256 NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 decreases activity EXP Everolimus results in decreased activity of NR1I3 protein CTD PMID:30203046 NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 multiple interactions ISO [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein CTD PMID:28947240 NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO Everolimus results in increased expression of PTGS2 mRNA; Everolimus results in increased expression of PTGS2 protein CTD PMID:15937522 NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978 		JBrowse link
G Ptk2 PTK2 protein tyrosine kinase 2 decreases expression ISO Everolimus results in decreased expression of PTK2 protein modified form CTD PMID:28258630 NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation		 ISO [letrozole co-treated with Everolimus] results in decreased phosphorylation of and affects the activity of RB1 protein; Everolimus results in decreased phosphorylation of and affects the activity of RB1 protein
Everolimus results in decreased phosphorylation of RB1 protein		 CTD PMID:16033851 PMID:16856892 NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262 		JBrowse link
G Rhoa ras homolog family member A decreases expression
multiple interactions		 ISO Everolimus results in decreased expression of RHOA protein
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased expression of RHOA protein]		 CTD PMID:28258630 PMID:30910523 NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133 		JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation		 ISO [letrozole co-treated with Everolimus] results in decreased phosphorylation of RPS6 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6 protein]
Everolimus results in decreased phosphorylation of RPS6 protein		 CTD PMID:16033851 PMID:21372221 PMID:22885370 PMID:23151917 PMID:23300809 More... NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 multiple interactions ISO Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]]
Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6KB1 protein]; Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]		 CTD PMID:16033851 PMID:19567381 PMID:24989011 NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression		 ISO Aspirin inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein] CTD PMID:19520256 NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483 		JBrowse link
G Src Rous sarcoma oncogene decreases expression ISO Everolimus results in decreased expression of SRC protein modified form CTD PMID:28258630 NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983 		JBrowse link
G Vim vimentin decreases expression ISO Everolimus results in decreased expression of VIM protein CTD PMID:28258630 NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637 		JBrowse link
ridaforolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle, aorta multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in increased expression of ACTA2 protein] CTD PMID:32949624 NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in decreased expression of CDH1 protein] CTD PMID:32949624 NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in increased expression of CDH2 protein] CTD PMID:32949624 NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in increased expression of FN1 protein] CTD PMID:32949624 NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases activity
multiple interactions		 ISO ridaforolimus results in decreased activity of MTOR protein
ridaforolimus inhibits the reaction [Radon results in increased expression of MTOR protein modified form]		 CTD PMID:32949624 NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140 		JBrowse link
G Snai1 snail family zinc finger 1 multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in increased expression of SNAI1 protein] CTD PMID:32949624 NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734 		JBrowse link
G Vim vimentin multiple interactions ISO ridaforolimus inhibits the reaction [Radon results in increased expression of VIM protein] CTD PMID:32949624 NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 22194
    role 22179
      biological role 22178
        immunomodulator 15707
          immunosuppressive agent 14576
            sirolimus 527
              everolimus 40
              ridaforolimus 7
Path 2
Term Annotations click to browse term
  CHEBI ontology 22194
    subatomic particle 22186
      composite particle 22186
        hadron 22186
          baryon 22186
            nucleon 22186
              atomic nucleus 22186
                atom 22186
                  main group element atom 22120
                    p-block element atom 22120
                      carbon group element atom 21921
                        carbon atom 21847
                          organic molecular entity 21847
                            heteroorganic entity 21503
                              organochalcogen compound 20992
                                organooxygen compound 20834
                                  carbon oxoacid 19625
                                    carboxylic acid 19621
                                      carboacyl group 18295
                                        univalent carboacyl group 18295
                                          carbamoyl group 18108
                                            carboxamide 18108
                                              lactam 8461
                                                macrolide lactam 840
                                                  sirolimus 527
                                                    everolimus 40
                                                    ridaforolimus 7
paths to the root